

**GAMBARAN INTERAKSI OBAT PADA PASIEN
RAWAT JALAN PENYAKIT JANTUNG KORONER
DI RUMAH SAKIT PKU MUHAMMADIYAH
GOMBONG TAHUN 2023**

SKRIPSI

Disusun Untuk Memenuhi Sebagian Persyaratan Mencapai Derajat Sarjana
Farmasi



Diajukan oleh
Karina Afaf Putri
NIM : C12020025

**PROGRAM STUDI FARMASI PROGRAM SARJANA
FAKULTAS ILMU KESEHATAN
UNIVERSITAS MUHAMMADIYAH GOMBONG
2024**

**GAMBARAN INTERAKSI OBAT PADA PASIEN
RAWAT JALAN PENYAKIT JANTUNG KORONER
DI RUMAH SAKIT PKU MUHAMMADIYAH
GOMBONG TAHUN 2023**

SKRIPSI

Disusun Untuk Memenuhi Sebagian Persyaratan Mencapai Derajat Sarjana
Farmasi



Diajukan oleh
Karina Afaf Putri
NIM : C12020025

**PROGRAM STUDI FARMASI PROGRAM SARJANA
FAKULTAS ILMU KESEHATAN
UNIVERSITAS MUHAMMADIYAH GOMBONG
2024**

HALAMAN PERSETUJUAN

GAMBARAN INTERAKSI OBAT PADA PASIEN RAWAT JALAN PENYAKIT JANTUNG KORONER DI RUMAH SAKIT PKU MUHAMMADIYAH GOMBONG TAHUN 2023

Telah disetujui dan dinyatakan Telah Memenuhi Syarat untuk diujikan Pada
Tanggal 13 Agustus 2024.

Yang dipersiapkan dan disusun oleh :

Karina Afaf Putri

Nim : C12020025

Susunan Tim Pembimbing :

1. Pembimbing 1 (apt. Chondrosuro Miyarso., M.Clin. Pharm) (.....)
2. Pembimbing 2 (apt. Anwar Sodik., M. Farm) (.....)

Mengetahui,

Ketua Program Studi Farmasi Program Sarjana

Fakultas Ilmu Kesehatan

Universitas Muhammadiyah Gombong



apt. Naelaz Zukhruf Wakhidatul Kiromah, M. Pharm., Sci

NIDN. 061819202

HALAMAN PENGESAHAN

GAMBARAN INTERAKSI OBAT PADA PASIEN RAWAT JALAN PENYAKIT JANTUNG KORONER DI RUMAH SAKIT PKU MUHAMMADIYAH GOMBONG TAHUN 2023

Yang dipersiapkan dan disusun oleh :

Karina Afaf Putri

Nim : C12020025

Telah dipertahankan di depan Tim Penguji pada tanggal 13 Agustus 2024

Susunan Tim Penguji :

1. Ketua Penguji (apt. Tri Cahyani Widiastuti., M. Sc) (.....)
2. Pembimbing 1 (apt. Chondrosuro Miyarso., M.Clin. Pharm)(.....)
3. Pembimbing 2 (apt. Anwar Sodik., M. Farm) (.....)

Mengetahui,

Ketua Program Studi Farmasi Program Sarjana

Fakultas Ilmu Kesehatan

Universitas Muhammadiyah Gombong



apt. Naelaz Zukhruf Wakhidatul Kiromah, M. Pharm., Sci

NIDN. 061819202

HALAMAN PERNYATAAN KEASLIAN PENELITIAN

Yang bertanda tangan dibawah ini:

Nama : Karina Afaf Putri
NIM : C12020025
Program studi : Farmasi Program Sarjana
Judul Penelitian : Gambaran Interaksi Obat Pada Pasien Rawat Jalan Penyakit Jantung Koroner Di Rumah Sakit PKU Muhammadiyah Gombong Tahun 2023

Menyatakan bahwa dalam Skripsi yang saya ajukan tidak terdapat karya yang pernah diajukan untuk memperoleh gelar kesarjanaan di suatu Perguruan Tinggi, dan sepanjang pengetahuan saya juga tidak terdapat karya atau pendapat yang pernah ditulis atau diterbitkan oleh orang lain, kecuali yang secara tertulis digunakan sebagai rujukan dalam naskah ini dan disebutkan dalam daftar pustaka dan sudah dinyatakan lolos uji plagiarisme. Apabila dikemudian hari diketemukan seluruh atau sebagian dari skripsi tersebut terdapat indikasi plagiarisme, saya bersedia menerima sanksi sesuai peraturan perundang-undangan yang berlaku.

Demikianlah pernyataan ini dibuat dalam keadaan sadar dan tanpa unsur paksaan dari siapapun.

Gombong, 26 Juli 2024

Yang menyatakan



Karina Afaf Putri

NIM. C12020025

HALAMAN BEBAS PLAGIARISME

Saya yang bertanda tangan dibawah ini:

Nama : Karina Afaf Putri
Tempat, Tanggal Lahir : Kebumen, 28 Mei 2002
Alamat : Jl. Saptamarga No.30, RT 01/RW 02, Desa
Sidayu, Kec. Gombong, Kab. Kebumen
No. telepon : 08132728164
Email : karinaafafputri@gmail.com

Dengan ini menyatakan yang sesungguhnya bahwa skripsi saya yang berjudul :

**GAMBARAN INTERAKSI OBAT PADA PASIEN RAWAT JALAN
PENYAKIT JANTUNG KORONER DI RUMAH SAKIT PKU
MUHAMMADIYAH GOMBONG TAHUN 2023**

Bebas dari plagiarisme dan bukan hasil karya orang lain.

Apabila dikemudian hari diketemukan seluruh atau sebagian dari skripsi tersebut terdapat indikasi plagiarisme, saya bersedia menerima sanksi sesuai peraturan perundang-undangan yang berlaku.

Demikianlah pernyataan ini dibuat dalam keadaan sadar dan tanpa unsur paksaan dari siapapun.

Gombong, 26 Juli 2024

Yang menyatakan



Karina Afaf Putri

NIM. C12020025

HALAMAN PERSETUJUAN PUBLIKASI

Sebagai civitas akademik Universitas Muhammadiyah Gombong, saya yang bertanda tangan dibawah ini:

Nama : Karina Afaf Putri

NIM : C12020025

Program studi : Farmasi Program Sarjana

Jenis karya : Skripsi

Demi pengembangan ilmu pengetahuan, menyetujui untuk memberikan kepada Universitas Muhammadiyah Gombong Hak Bebas Royalti Noneksklusif (*Non-exclusive Royalty-Free Right*) atas skripsi saya yang berjudul:

GAMBARAN INTERAKSI OBAT PADA PASIEN RAWAT JALAN PENYAKIT JANTUNG KORONER DI RUMAH SAKIT PKU MUHAMMADIYAH GOMBONG TAHUN 2023

Beserta perangkat yang ada (jika diperlukan). Dengan Hak bebas Royalti Noneksklusif ini Universitas Muhammadiyah Gombong berhak menyimpan, mengalihmedia/formatkan, mengelola dalam bentuk pangkalan data, merawat dan mempublikasikan tugas akhir saya selama tetap mencantumkan nama saya sebagai penulis/pencipta dan sebagai pemilik Hak Cipta.

Demikian pernyataan ini saya buat dengan sebenarnya.

Dibuat di : Gombong, Kebumen

Pada Tanggal 26 Juli 2024

Yang menyatakan



Karina Afaf Putri

NIM. C12020025

KATA PENGANTAR

Assalamu'alaikum warahmatullahi wabarakaatuh

Alhamdulillahirabbil'aalamiin

Puji Syukur penulis panjatkan kehadiran Allah SWT atas Rahmat dan hidayah-Nya, sehingga penulis dapat menyelesaikan skripsi ini dengan judul **“Gambaran Interaksi Obat Pada Pasien Rawat Jalan Penyakit Jantung Koroner di Rumah Sakit PKU Muhammadiyah Gombong Tahun 2023”**. Skripsi ini disusun untuk memenuhi persyaratan ujian hasil di Universitas Muhammadiyah Gombong.

Sholawat serta salam mari kita curahkan kepada Nabi Allah, Muhammad SAW yang kita nantikan safa'atnya dihari akhir nanti. Skripsi ini tidak lepas dari bimbingan dan bantuan dari berbagai pihak, baik secara moril ataupun materi sehingga penulis mengucapkan terimakasih kepada :

1. Dr. Hj, Herniyatun, M. Kep.,Sp. Mat Selaku Rektor Universitas Muhammadiyah Gombong.
2. Eka Riyanti, M. Kep.,Sp. Kep. Mat selaku Dekan Fakultas Ilmu kesehatan Universitas Muhammadiyah Gombong.
3. Apt. Naelaz Zukhruf Wakhidatul Kiromah, M. Pharm, Sci selaku Ketua Program Studi Farmasi Program Sarjana Universitas Muhammadiyah Gombong.
4. Apt. Chondrosuro Miyarso, M. Clin, Pharm selaku pembimbing 1 yang telah meluangkan waktu, pemikiran, masukan dalam memberikan bimbingan kepada penulis.
5. Apt. Anwar Sodik, M. Farm selaku dosen pembimbing 2 yang telah meluangkan waktu, pemikiran, masukan dalam memberikan bimbingan kepada penulis.
6. Seluruh civitas akademika Universitas Muhammadiyah Gombong yang telah memberikan bantuannya untuk menyelesaikan skripsi ini.

7. Kedua orang tua yang mendoakan dan memberikan dukungan baik moril, maupun materil termasuk motivasi dan semangat sehingga penulis dapat mengerjakan skripsi ini dengan baik dan lancar.
8. Seluruh pihak Rumah Sakit PKU Muhammadiyah Gombong, diklat dan unit rekam medis yang telah memberikan bantuannya selama penelitian.
9. Seluruh teman-teman dan semua pihak yang telah memberikan semangat, dukungan dan membantu dalam menyelesaikan skripsi ini.

Penulis menyadari bahwa dalam skripsi ini masih jauh dari kesempurnaan, Sehingga penulis mengharapkan kritik dan saran dari berbagai pihak demi terwujudnya karya yang lebih baik kedepannya. Sebagai ungkapan terima kasih, penulis mendoakan semoga bantuan yang telah diberikan kepada penulis mendapatkan balasan yang terbaik dari Allah SWT.

Aamiin yaa rabbal'alamiin

Wassalamu'alaikum warahmatullahi wabarakaatuh

Gombong, 26 Juli 2024

Penulis



(Karina Afaf Putri)

HALAMAN PERSEMBAHAN

“Allah tidak membebani seseorang melainkan sesuai dengan kesanggupannya”.

(Qs. Al Baqarah ayat 286)

Bismillahirrahmaanirrahiim

Alhamdulillah rabbil'alamiin segala puji dan syukur kehadiran Allah SWT atas segala rahmat dan karunia-Nya, sehingga saya dapat menyelesaikan skripsi ini dengan tepat waktu. Adapun skripsi ini saya persembahkan untuk :

1. Kedua orangtua saya tercinta Bapak Sugeng Budi Setiawan dan Ibu Neni Kisnurlinah yang selama ini telah memberikan dukungan, motivasi, semangat serta doa yang setiap waktu selalu dipanjatkan, dan yang telah membiayai perkuliahan saya
2. Adek saya Raziq Hanan Setiawan yang memberikan dukungan, semangat.
3. Seluruh keluarga besar bapak dan ibu yang selalu memberikan semangat dan motivasinya kepada saya.
4. Teman-teman terdekat saya yang selalu memberikan motivasi dan semangatnya kepada saya.
5. Seluruh teman-teman dari prodi farmasi angkatan 2020 yang memberikan semangat dalam belajar selama perkuliahan.

**PROGRAM STUDI FARMASI PROGRAM SARJANA
FAKULTAS ILMU KESEHATAN**

UNIVERSITAS MUHAMMADIYAH GOMBONG

Skripsi, Juli 2024

Karina Afaf Putri¹⁾, Chondrosuro Miyarso²⁾, Anwar Sodik³⁾

ABSTRAK

**GAMBARAN INTERAKSI OBAT PADA PASIEN RAWAT JALAN
PENYAKIT JANTUNG KORONER DI RUMAH SAKIT PKU
MUHAMMADIYAH GOMBONG TAHUN 2023**

Latar Belakang: Penyakit Jantung Koroner atau sering disebut PJK di Indonesia dilaporkan menjadi penyakit urutan pertaman yang menyebabkan kematian sebesar 26,4%. Pada pasien PJK biasanya disertai dengan penyakit penyerta, sehingga membutuhkan banyak obat untuk terapinya. Penggunaan berbagai macam obat dapat beresiko menyebabkan interaksi obat. Terjadinya interaksi obat dapat menimbulkan permasalahan pengobatan, meningkatkan biaya dan mengganggu efektivitas pengobatan

Tujuan Penelitian: Penelitian ini bertujuan untuk mengetahui gambaran interaksi obat pada pasien rawat jalan penyakit jantung koroner di Rumah Sakit PKU Muhammadiyah Gombong tahun 2023.

Metode penelitian: Penelitian ini menggunakan metode deskriptif non eksperimental secara retrospektif dengan metode purposive sampling. Data obat yang diperoleh dianalisis menggunakan aplikasi *Medscape* dan *Drugs.com*. Sampel yang termasuk kedalam kriteria inklusi berjumlah 230.

Hasil penelitian: Hasil yang didapat menunjukkan bahwa dari 230 pasien terdapat 223 (97%) pasien yang berpotensi mengalami interaksi obat. Mayoritas interaksi obat yang terjadi berdasarkan tingkat keparahan yaitu pada tingkat Moderat sebanyak 652 kasus (82%) paling banyak terjadi pada obat aspirin dengan bisoprolol, minor 83 kasus (10%) interaksi yang paling banyak pada obat aspirin dengan furosemide, dan mayor 57 kasus (7%) paling banyak terjadi pada obat amlodipine dengan simvastatin. Berdasarkan mekanisme interaksi obat yang paling banyak terjadi yaitu interaksi dengan mekanisme farmakodinamika dengan jumlah 52 kasus (58,43%), farmakokinetik 7 kasus (7,87%)

Kesimpulan: Interaksi obat yang terjadi pada pasien rawat jalan penyakit jantung koroner di Rumah sakit PKU Muhammadiyah Gombong paling banyak terjadi pada tingkat keparahan Moderat sebanyak 652 kasus (82%), berdasarkan mekanisme interaksi obat paling banyak terjadi pada mekanisme interaksi obat farmakodinamika sejumlah 52 kasus (58,43%).

Rekomendasi: Bagi peneliti selanjutnya melakukan penelitian secara prospektif kepada pasien sehingga dapat diketahui secara detail terkait interaksi obat

Kata kunci: *Penyakit Jantung Koroner (PJK), interaksi obat, pasien rawat jalan.*

¹⁾Mahasiswa Universitas Muhammadiyah Gombong

²⁾Dosen Universitas Muhammadiyah Gombong

³⁾Dosen Universitas Muhammadiyah Gombong

UNDERGRADUATE PHARMACY STUDY PROGRAM
FACULTY OF HEALTH SCIENCES
UNIVERSITAS MUHAMMADIYAH GOMBONG
Thesis, July 2024
Karina Afaf Putri¹⁾, Chondrosuro Miyarso²⁾, Anwar Sodik³⁾

ABSTRACT

OVERVIEW OF DRUG INTERACTIONS IN CORONARY HEART DISEASE OUTPATIENT AT PKU MUHAMMADIYAH GOMBONG HOSPITAL IN 2023

Background: Coronary Heart Disease (CHD) or often called PJK in Indonesia is reported to be the first disease that causes death by 26.4%. In PJK patients, it is usually accompanied by comorbidities, so it requires a lot of drugs for therapy. The use of various drugs can cause drug interactions. The occurrence of drug interactions can cause treatment problems, increase costs and interfere with the effectiveness of treatment.

Objective: This study aims to determine the description of drug interactions in outpatients with coronary heart disease at PKU Muhammadiyah Gombong Hospital in 2023.

Methods: This study used a non-experimental descriptive method retrospectively with a purposive sampling method. The drug data obtained were analyzed using the *Medscape* and *Drugs.com* applications. The number of samples included in the inclusion criteria was 230.

Result: The results obtained showed that out of 230 patients, 223 (97%) patients had the potential to experience drug interactions. The majority of drug interactions that occurred based on severity were at a Moderat level of 652 cases (82%) most commonly occurs with aspirin and bisoprolol, minor 83 cases (10%) The most common interaction between aspirin and furosemide, and major 57 cases (7%). Based on the most common drug interaction mechanism, interactions with pharmacodynamic mechanisms occurred with 52 cases (58,43%), pharmacokinetics 7 cases (7.87%)

Conclusion: Drug interactions that occurred in outpatients with coronary heart disease at the PKU Muhammadiyah Gombong Hospital mostly occurred at a Moderat level of severity of 652 cases (82%), based on the most common drug interaction mechanism occurred in the pharmacodynamic drug interaction mechanism of 52 cases (58,43%).

Recommendation: For further researchers, conducting prospective research on patients can provide detailed information regarding drug interactions.

Keywords: *Coronary Heart Disease, drug interaction, outpatients.*

¹⁾ Student of Universitas Muhammadiyah Gombong


²⁾ Lecturer of Universitas Muhammadiyah Gombong

³⁾ Lecturer of Universitas Muhammadiyah Gombong

DAFTAR ISI


HALAMAN JUDUL	i
HALAMAN PERSETUJUAN	ii
HALAMAN PENGESAHAN	iii
HALAMAN PERNYATAAN KEASLIAN PENELITIAN	iv
HALAMAN BEBAS PLAGIARISME	v
HALAMAN PERSETUJUAN PUBLIKASI	vi
KATA PENGANTAR	vii
HALAMAN PERSEMBAHAN	ix
ABSTRAK	x
ABSTRACT	xi
DAFTAR ISI	xii
DAFTAR TABEL	xiv
DAFTAR GAMBAR	xv
BAB I	1
PENDAHULUAN	1
1.1 Latar Belakang	1
1.2 Rumusan Masalah	3
1.3 Tujuan Penelitian	3
1.4 Manfaat Penelitian	4
1.5 Keaslian Penelitian	4
BAB II	7
TINJAUAN PUSTAKA	7
2.1 Jantung Koroner	7
2.2 Interaksi Obat	13
2.3 Kerangka Teori	16
2.4 Kerangka Konsep	17
BAB III	18
METODOLOGI PENELITIAN	18
3.1 Desain atau Rancangan Penelitian	18
3.2 Populasi dan Sampel	18
3.3 Tempat Penelitian	19

3.4	Definisi Oprasional.....	19
3.5	Instrumen Penelitian.....	20
3.6	Etika Penelitian.....	20
3.7	Teknik Pengumpulan Data	21
3.8	Teknik Analisi Data.....	22
BAB IV		23
HASIL DAN PEMBAHASAN		23
4.1	Hasil Penelitian.....	23
4.2	Pembahasan Hasil Penelitian.....	29
4.3	Keterbatasan Penelitian	37
BAB V.....		38
KESIMPULAN DAN SARAN		38
5.1	Kesimpulan.....	38
5.2	Saran	38
DAFTAR PUSTAKA		39
LAMPIRAN.....		43



DAFTAR TABEL

Tabel 1. 1 Keaslian Penelitian	5
Tabel 3. 1 Definisi Operasional.....	19
Tabel 4. 1 Gambaran Distribusi Pasien Berdasarkan Jenis Kelamin dan Umur ..	23
Tabel 4. 2 Gambaran Distribusi Penyakit Penyerta dan Komplikasi pada pasien PJK	24
Tabel 4. 3 Gambaran Karakteristik Interaksi Obat.....	26
Tabel 4. 4 Gambaran Interaksi Obat Berdasarkan Tingkat Kearahan pada Aplikasi <i>Medscape</i>	26
Tabel 4. 5 Gambaran Interaksi Obat Berdasarkan Tingkat Keparahan pada Aplikasi <i>Drugs.com</i>	26
Tabel 4. 6 Mekanisme Interaksi Obat Pada Pasien Penyakit Jantung Koroner....	27
Tabel 4.7 10 Kombinasi Obat yang Paling Banyak Berpotensi Terjadi Interaksi Obat Berdasarkan Aplikasi <i>Medscape</i>	27
Tabel 4.8 10 Kombinasi Obat Yang Paling Banyak Berpotensi Terjadi Interaksi Obat Berdasarkan Aplikasi <i>Drugs.com</i>	27



DAFTAR GAMBAR

Gambar 2.1 Kerangka Teori	16
Gambar 2.2 Kerangka Konsep.....	17



BAB I

PENDAHULUAN

1.1 Latar Belakang

Penyakit Jantung Koroner atau yang sering dikenal dengan PJK ialah suatu penyakit dari system kardiovaskuler yang menjadi salah satu penyebab pertama dan paling sering terjadi kematian yang terjadi pada negara maju dan berkembang. Penyakit tersebut bukanlah penyakit yang menular namun semakin hari semakin meningkat jumlah orang yang terkena penyakit jantung koroner di kalangan dunia maupun di negara salah satunya Indonesia. Penyakit jantung koroner pada tahun 2020 merupakan tahun dimana penyakit tersebut menjadi penyebab seseorang mengalami kematian. Hasil yang didapatkan pada tahun 2020 tersebut sebesar 36% dari semua kematian, jumlah tersebut lebih tinggi dua kali dibandingkan dengan angka kematian akibat kanker. Laporan yang diterima di negara Indonesia penyakit jantung koroner tersebut menjadi kriteria utama dari semua kematian, dengan jumlah 26,4% dan empat kali lebih besar dari penyakit kanker yang menyebabkan kematian (PERKI, 2018).

Hasil Riset Kesehatan Dasar (2018) mengatakan bahwasannya prevelensi penyakit jantung termasuk pada kriteria jantung bawaan berdasarkan diagnosa dokter berkisar 1,5% atau 1.017.290. Masyarakat yang tinggal di perkotaan memiliki prevelensi sedikit lebih tinggi (1,6%) dibandingkan dengan yang tinggal di pedesaan (1,3%). Prevelensi penyakit jantung koroner di Jawa Tengah yang terdiagnosis oleh dokter mencapai 1,6% atau 132.565. (Riskesdas Jawa Tengah, 2018).

Stockley's pada tahun 2015 menyebutkan bahwasannya interaksi obat ialah suatu kejadian interaksi yang disebabkan karena adanya penggunaan dua obat atau lebih secara bersamaan yang akhirnya menyebabkan kinerja dari obat tersebut mengalami efek samping yang berbeda. Terjadinya interaksi dari penggunaan obat dapat melalui berbagai proses, yaitu adanya perubahan farmakokinetik dan farmakodinamik. Perubahan farmakokinetik meliputi absorpsi, distribusi, metabolisme, dan

ekskresi obat, sedangkan pada farmakodinamik perubahan yang dapat terjadi ialah berupa efek samping dari penggunaan obat yang satu macam yang berlawanan. Efek samping dari penggunaan obat yang berlawanan akan menjadi pengganggu dan menyebabkan suatu kejadian yang tidak diinginkan seperti penurunan efek obat serta memberikan efek yang signifikan berbahaya dari penggunaan terapi yang tidak maksimal (NP & Dandan, 2019).

Masalah komplikasi yang serius seperti hipertensi, ginjal, stroke, dan diabetes seringkali muncul pada usia lanjut. Sehingga usia lanjut membutuhkan jasa kesehatan yang lebih besar dari pada anggota usia lain, penggunaan obat-obat polifarmasi banyak digunakan pada usia lanjut (Islamiyah, 2021). Jumlah penggunaan obat dapat mempengaruhi kerja obat yang dapat menyebabkan efek interaksi pada obat meningkat. Oleh karena itu, penggunaan obat polifarmasi dapat menyebabkan terjadinya suatu interaksi pada obat (Parulian et al., 2019).

Penelitian (Saputri & Dewi, 2023) menyebutkan bahwa hasil kejadian interaksi obat yang diresepkan pada pasien rawat jalan dengan diagnose penyakit jantung koroner disertai dengan indikasi lainnya suatu kejadian interaksi paling banyak terjadi pada obat clopidogrel dengan lansoprazole sebanyak 108 interaksi, spironolakton dengan furosemide sebanyak 31 interaksi, simvastatin dan amlodipine sebanyak 26 interaksi.

Penelitian tentang interaksi obat pada pasien jantung koroner juga pernah dilakukan oleh (Raja et al., 2022) Mendapatkan hasil yaitu berdasarkan analisis interaksi obat dari total 75 resep pasien rawat jalan penderita penyakit jantung koroner terdapat 73 resep (97,33%) yang memiliki potensi terjadinya interaksi obat dengan jumlah 81 jenis interaksi, dengan paling banyak jenis interaksi yaitu Moderat berjumlah 66 kasus (81,48%), Tingkat minor berjumlah 8 kasus (9,88%), dan pada tingkat major berjumlah 7 kasus (8,64%). Aspirin dengan bisoprolol merupakan obat yang paling sering berinteraksi yaitu sebanyak 35 kasus (47,94%). Interaksi obat yang terjadi berdasarkan mekanisme interaksi obat paling

banyak terjadi yaitu interaksi dengan mekanisme farmakodinamika yang berjumlah 57 kasus (70,37%).

Hasil dari studi pendahuluan yang telah dilakukan pada bulan September di Rumah Sakit PKU Muhammadiyah Gombong data pasien rawat jalan tahun 2023 terdapat 1359 pasien yang terdiagnosis penyakit jantung koroner. Rumah sakit tersebut merupakan salah satu rumah sakit yang berada di Kabupaten Kebumen yang bertipe B dengan naungan Muhammadiyah.

Berdasarkan uraian latar belakang diatas, maka akan dilakukan penelitian karena berdasarkan hasil studi pendahuluan di rumah sakit PKU Muhammadiyah Gombong masih banyak terdapat kasus penyakit jantung koroner sehingga peneliti sangat tertarik untuk melakukan penelitian terkait interaksi obat pada pasien jantung koroner yang berjudul “Gambaran Interaksi Obat pada Pasien Penyakit Jantung Koroner Rawat Jalan Rumah Sakit PKU Muhammadiyah Gombong”. Adapun tujuan dari penelitian ini yaitu mengetahui bagaimana interaksi yang terjadi pada pengobatan pasien penyakit jantung koroner di Rumah Sakit PKU Muhammadiyah Gombong berdasarkan Tingkat keparahannya.

1.2 Rumusan Masalah

Berdasarkan latar belakang yang telah dijelaskan maka rumusan masalah pada penelitian ini yaitu bagaimana gambaran interaksi obat pada pasien penyakit jantung koroner rawat jalan di RS PKU Muhammadiyah Gombong?

1.3 Tujuan Penelitian

Penelitian ini memiliki Tujuan Umum dan Khusus yaitu :

1.3.1 Tujuan umum

Menganalisis suatu interaksi obat yang terjadi pada pengobatan penyakit jantung koroner pada pasien rawat jalan di RS PKU Muhammadiyah Gombong

1.3.2 Tujuan Khusus

1.3.2.1 Menganalisis tingkat keparahan interaksi obat pada pasien rawat jalan penyakit jantung koroner di RS PKU Muhammadiyah Gombong apakah masuk kedalam level minor, mayor, atau moderat.

1.3.2.2 Menganalisis mekanisme interaksi obat pada pasien rawat jalan penyakit jantung koroner di RS PKU Muhammadiyah Gombong apakah masuk kedalam interaksi farmakodinamik, farmakokinetik, atau tidak diketahui

1.4 Manfaat Penelitian

Adapun manfaat yang diharapkan pada penelitian ini yaitu sebagai berikut :

1.4.1 Manfaat bagi Pengembangan Ilmu (Bidang Kefarmasian)

Pengembangan penelitian dan sebagai referensi penelitian selanjutnya mengenai gambaran interaksi obat pada pasien rawat jalan penyakit jantung koroner di Rumah Sakit PKU Muhammadiyah Gombong

1.4.2 Manfaat Bagi Praktisi (Tempat Penelitian)

Penelitian ini bagi praktisi memiliki fungsi untuk menyusun panduan klinis yang lebih baik dalam mengelola pasien dengan penyakit jantung koroner serta dapat menghindari penggunaan obat-obatan yang mungkin berinteraksi secara negatif, sehingga mengurangi resiko efek samping dan komplikasi

1.4.3 Manfaat Bagi Masyarakat

Sebagai tambahan wawasan akan pentingnya kesehatan serta menghindari efek samping yang terjadi dari interaksi yang terjadi pada pengobatan Penyakit Jantung Koroner

1.5 Keaslian Penelitian

Terdapat 3 keaslian penelitian yang digunakan dan diuraikan dibawah ini :

Tabel 1. 1 Keaslian Penelitian

Nama Peneliti, Tahun peneliti	Judul Penelitian	Metode Penelitian	Hasil Penelitian	Perbedaan dan Persamaan dengan Penelitian ini
Meliana Saputri, Sinta Ratna Dewi 2023	Potensi Interaksi Polifarmasi Pasien Jantung Koroner (PJK) di Rumah Sakit I.A. Moeis Samarinda	Deskriptif, non eksperimental	Hasil penelitian menunjukkan interaksi obat ditemukan paling banyak pada obat clopidogrel dan lansoprazole dengan jumlah 108, spironolakton dan furosemide berjumlah 31, dan pada obat simvastatin dan amlodipine brjumlah 26	Perbedaan : Tempat dan Waktu Penelitian Persamaan : Metode penelitian yang digunakan
Muhammad Raja Fachri Buldan, Umi Yuniart, dan Fetri Lestari 2022	Analisis Interaksi Obat Pada Pasien Rawat Jalan Penderita Penyakit Jantung Koroner di Salah Satu Rumah Sakit di Kota bandung	Observasional	Hasil penelitian dari 75 resep diketahui 73 resep(97,33%) mengalami interaksi obat. Tingkat keparahan interaksi obat yang paling banyak yaitu interaksi pada tingkat Moderat dengan jumlah 66 kasus (81,48%), kemudian interaksi pada tingkat minor dengan jumlah 8 kasus (9,88%), dan interaksi pada tingkat major berjumlah 7 kasus (8,64%). Aspirin- bisoprolol merupakan obat yang paling sering berinteraksi yaitu berjumlah 35 kasus. Berdasarkan mekanisme interaksi obat interaksi yang paling banyak yaitu interaksi obat berdasarkan mekanisme	Perbedaan : Metode Penelitian,Tempat dan Waktu Penelitian Persamaan : Penyakit yang akan diteliti

			farmakodinamika berjumlah 57 kasus (70,37)	
Rakhmadani Gadis Aprilianti, Beta Herilla, Lilik Nur Hidayati, 2022	Gambaran Interaksi Obat Penyakit Jantung Koroner Dengan Sindrom Metabolik Pada Pasien Rawat Jalan Di RS TK II Dr. Soepraoen Malang	Observasional	Hasil dari penelitian ini terdapat 82 resep yang mengalami interaksi obat yang signifikan. interaksi obat yang paling banyak terjadi yaitu dengan tingkat Moderat sebanyak (81,48%) contohnya aspirin dengan candesartan dan bisoprolol dengan amlodipine. Aspirin dengan bisoprolol merupakan interaksi yang sering terjadi dengan level minor dengan jumlah (17,74%). Bisoprolol termasuk obat yang paling banyak digunakan dengan jumlah (22,18%) dan beta blocker termasuk golongan obat yang paling banyak digunakan.	Perbedaan :Metode Penelitian, Tempat dan Waktu Penelitian Persamaan : Masalah yang akan diteliti, dan penyakit yang akan diteliti

DAFTAR PUSTAKA

- Agustin, O. A., & Fitrianingsih. (2020). Kajian Interaksi Obat Berdasarkan Kategori Signifikansi Klinis Terhadap Pola Peresepan Pasien Rawat Jalan Di Apotek X Jambi. *E-SEHAD*, 1(1), 1–10.
- Amisi, W. G., Nelwan, J. E., & Kolibu, F. K. (2018). Hubungan antara Hipertensi dengan Kejadian Penyakit Jantung Koroner pada Pasien yang Berobat di Rumah Sakit Umum Pusat Prof. Dr. R. D. Kandou Manado. *Kesmas*, 7(4), 1–7.
- Andriani, Y., Robiyanto, & Nurmainah. (2019). *Profil Pasien Pengguna Obat Jantung Koroner Rawat Inap Di RSUD Sultan Syarif Mohammad Alkadrie Pontianak*.
- Aprilianti, R. G., Sekti, B. H., & Hidayati, L. N. (2022). Gambaran Interaksi Obat Penyakit Jantung Koroner Dengan Sindrom Metabolik Pada Pasien Rawat Jalan Di Rs Tk Ii Dr. Soepraoen Malang. *Jurnal Riset Kefarmasian Indonesia*, 4(1), 59–73. <https://doi.org/10.33759/jrki.v4i1.222>
- Arfania, M., Frianto, D., Amallia, S., Yashna Kusuma Adi Saputra, M., Cindika Sagala, B., Ayu Wulandari, S., & Amelia, A. (2023). Gambaran Interaksi Penggunaan Obat Gagal Jantung Pada Pasien Komplikasi : Riview Artikel. *Journal Of Social Science Research*, 3.
- Bailie, G. R., Johnson, C. A., Mason, N. A., & Peter, W. L. St. (2021). *Pocket guide of drug interactions*. 3.
- Bailie, G. R., Johnson, C. A., Mason, N. A., & Peter, W. L. S. (2009). *Pocket guide of drug interactions*.
- Black, J. dan Hawks, J. (2014). *Keperawatan Medikal Bedah : Manajemen Klinis untuk Hasil yang Diharapkan*. Salemba Emban Patria.
- Dasopang, E. S., Harahap, U., & Lindarto, D. (2015). Polipharmacy and Drug Interactions in Elderly Patients with Metabolic Diseases. *Indonesian Journal of Clinical Pharmacy*, 4(4), 235–241. <https://doi.org/10.15416/ijcp.2015.4.4.235>
- Ghani, L., Susilawati, M. D., & Novriani, H. (2016). Faktor Risiko Dominan

- Penyakit Jantung Koroner di Indonesia. *Buletin Penelitian Kesehatan*, 44(3), 153–164. <https://doi.org/10.22435/bpk.v44i3.5436.153-164>
- Islamiyah, A. N. (2021). Telaah Potensi Interaksi Obat Resep Polifarmasi Klinik Jantung pada Salah Satu Rumah Sakit di Bandung. *Kartika : Jurnal Ilmiah Farmasi*, 8(1), 25. <https://doi.org/10.26874/kjif.v8i1.283>
- Karyatin, K. (2019). Faktor-Faktor Yang Berhubungan Dengan Kejadian Penyakit Jantung Koroner. *Jurnal Ilmiah Kesehatan*, 11(1), 37–43. <https://doi.org/10.37012/jik.v11i1.66>
- Katzung, B. G. (2018). *Basic and Clinical Pharmacology 14th Edition*. https://books.google.co.uk/books?id=W5ADwAAQBAJ%0Ahttp://books.google.de/books/about/Basic_and_Clinical_Pharmacology_12_E.html?id=Oig2eTjI1VAC&pgis=1
- Lemone, P, Burke, & B. (2015). *Buku Ajar Keperawatan Medikal Bedah (5th ed.; T. Utami, ed.)*. Buku Kedokteran ECG.
- Listiani, R. A. P. (2020). *Potensi Interaksi Obat Antidiabetik Pada Pasien Diabetes Melitus Tipe 2. Dm*.
- Mala, S., Afiah, A. S. N., & Dunggio, M. S. (2019). Gambaran profil lipid pada penderita penyakit jantung koroner di rumah sakit umum daerah Dr. H. Chasan Boesoirie Ternate. *Kieraha Medical Jurnal*, 1(1), 54–59.
- NHLBI. (2015). *National Heart, Lung and Blood Institute : Coronary Heart Disease*.
- NP, B. H., & Dandan, K. L. (2019). Identifikasi potensi interaksi antar obat pada resep umum di Apotek Kimia Farma 58 Kota Bandung bulan April 2019. *Farmaka*, 17(April), 57–64.
- Nur'aini, Banu Kuncoro, Y. Y. (2019). Evaluation of Coronary Heart Drug Interactions in Patients Hospitalised in Tangerang General Hospital 2017. *Jurnal Farmagazine*, VI(1), 38–46.
- Nurdiyanti, R. (2024). Kajian Interaksi Bisoprolol Pada Pasien Rawat Inap Di Rumah Sakit Islam Sultan Agung Semarang Periode 2018. *Reactions Weekly*, 2008(1), 72–72. <https://doi.org/10.1007/s40278-024-58966-4>
- Parulian, L., Listiyanti, E., Kumala Hati, A., & Sunnah, I. (2019). *Analisis*

Hubungan Polifarmasi Dan Interaksi Obat Pada Pasien Rawat Jalan Yang Mendapatkan Obat Hipertensi Di Rsp. Dr. Ario Wirawan Periode Januari-Maret 2019. 02(August), 4–7.

PERKI. (2018). Pedoman Tatalaksana Sindrom Koroner Akut Edisi Ke Empat. In *Medical Journal of Australia* (Vol. 184, Issue 8 SUPPL., pp. 516–525). <https://doi.org/10.5694/j.1326-5377.2007.tb01292.x>

Rahayu, S., & Hendera, H. (2018). Interaksi Antar Obat Pada Peresepan Pasien Rawat Inap Pediatrik Rumah Sakit X Dengan Menggunakan Aplikasi Medscape. *Journal of Current Pharmaceutical Sciences*, 1(2), 75–80.

Rahmawati, D. U., & Mutmainah, N. (2021). Kajian Interaksi Obat Potensial Pada Pasien Penyakit Jantung Koroner Rawat Inap di RSUD Moewardi Tahun 2018. *Proceeding of The URECOL*, 417–428.

Raja, M., Buldan, F., Yuniarni, U., & Lestari, F. (2022). *Analisis Interaksi Obat Pada Pasien Rawat Jalan Penderita Penyakit Jantung Koroner di Salah Satu Rumah Sakit di Kota Bandung*. 102–111.

Riskesdas Jawa Tengah. (2018). Riskesdas provinsi jawa tengah. In *Kementerian Kesehatan RI*.

Roimawati. (2020). *Analisis Kuantitas Penggunaan Obat-obatan Kardiovaskular Untuk Pasien Rawat Jalan di RS*. https://dspace.uui.ac.id/bitstream/handle/123456789/28792/14613299_RiskaRoimawati.pdf?sequence=1&isAllowed=y

Rosjidi, & Nurhidayat. (2014). *Buku Ajar Perawatan Cedera Kepala dan Stroke*. Ardhana Media.

Saputra, L. (2014). *Buku Saku Keperawatan Pasien dengan Gangguan Fungsi Kardiovaskular*. Binarupa Aksara Publisher.

Saputri, M., & Dewi, S. R. (2023). Potensi Interaksi Polifarmasi Pasien Jantung Koroner (PJK) di Rumah Sakit I.A. Moeis Samarinda. *Jurnal Sains Dan Kesehatan*, 5(2), 109–114. <https://doi.org/10.25026/jsk.v5i2.1709>

Shane, B. . (2016). An Overview of Polypharmacy in Geriatric Patients. *Intech*, 11(tourism), 13. <https://www.intechopen.com/books/advanced-biometric-technologies/liveness-detection-in-biometrics>

- Sherwood, L. (2014). *Fisiologi Manusia : dari sel ke sistem*. (8th ed.). EGC.
- Smeltzer, S. C. (2014). *Keperawatan Medical-Bedah*. EGC.
- Sutejo, I. R., Nurqistan, H. D., Rasyada, I., & Yuniasih, N. N. (2016). *Kandungan Fitoesterogen Ekstrak Etanolik Akar Rami (Boehmeria nivea) Menurunkan Kadar Kolesterol Tikus Yang Diovarektomi Phytoesterogen Component Of Ethanolic Root Extract Of Flaxseed (Boehmeria Nivea) Decreases Cholesterol Serum Level On Ovariectomiz*.
- Tajudin, T., Faradiba, V., & Nugroho, I. D. W. (2019). Analisis Kombinasi Penggunaan Obat pada Pasien Jantung Koroner dengan Penyakit Penyerta di Rumah Sakit X Cilacap tahun 2019. *Jurnal Ilmiah Kefarmasian*, 6–13. <http://e-jurnal.stikesalirsyadclp.ac.id/index.php/jp%0AAnalisis>
- Wahidah. (2019). PJK (Penyakit Jantung Koroner) dan SKA (Sindrome Koroner Akut) dari Prespektif Epidemiologi CHD (Coronary Heart Disease) and ACS (Acute Coronary Syndrome) from an Epidemiological Perspective. *Jurnal Kesehatan Masyarakat*, 6(1), 54–65.
- Wahyudin, E. (2022). *Analisis Kombinasi Penggunaan Obat Pada Pasien Jantung Koroner Di Rumah Sakit Universitas Hasanuddin Makassar*. 26(1), 15–18. <https://doi.org/10.20956/mff.v26i1.18754>
- wijaya, A.S dan Putri, Y. . (2013). *Keperawatan Medikal Bedah 2, Keperawatan Dasar Teori dan Contoh Askep*. Nuha Medika.



Lampiran 1. Surat Izin Penelitian



UNIVERSITAS MUHAMMADIYAH GOMBONG
LEMBAGA PENELITIAN DAN PENGABDIAN MASYARAKAT
Sekretariat : Jl. Yos Sudarso no. 461 Gombong, Kebumen Telp. (0287)472433
Email: lppm@unimugo.ac.id Web: <http://unimugo.ac.id/>

No : 459.5/II.3.AU/PN/V/2024
Hal : Permohonan Ijin
Lampiran : -

Gombong, 21 Mei 2024

Kepada :

Yth. Kepala Diklat Rumah Sakit PKU Muhammadiyah Gombong

Assalamu'alaikum Wr. Wb.

Teriring do'a semoga kita dalam melaksanakan tugas sehari-hari senantiasa mendapat lindungan dari Allah SWT. Aamiin

Schubungan dengan akan dilaksanakannya penelitian bagi mahasiswa Farmasi Program Sarjana Universitas Muhammadiyah Gombong, dengan ini kami mohon kesediaannya untuk memberikan ijin kepada mahasiswa kami:

Nama : Karina Afaf Putri
NIM : C12020025
Judul Penelitian : Gambaran Interaksi Obat pada Pasien Rawat Jalan Penyakit Jantung Koroner di Rumah Sakit PKU Muhammadiyah Gombong Tahun 2023
Keperluan : Ijin Penelitian

Demikian atas perhatian dan ijin yang diberikan kami ucapkan terima kasih.

Wassalamu'alaikum Wr.Wb.

Kepala LPPM
Universitas Muhammadiyah Gombong



Amika Dwi Asti, M.Kep

UNIMUGO

Berakhlak & Mencerahkan

Lampiran 2. Surat Balasan Izin Penelitian



Gombong, 15 Dzulqaidah 1445 H
24 Mei 2024 M

Nomor : 787/IV.6.AU/D/VII/2024
Hal : Jawaban Izin Penelitian

Kepada Yth.
Kepala LPPM Universitas Muhammadiyah Gombong
Di tempat

Assalamu'alaikum warahmatullaahi wa barakaatuh.

Teriring doa semoga rahmat dan hidayah Allah Subhaanahu Wa Ta'aala senantiasa menyertai kita dalam menjalankan tugas sehari-hari. Aamiin.

Menanggapi surat Saudara tentang permohonan ijin Penelitian bagi Mahasiswa Universitas Muhammadiyah Gombong atas nama **Karina Afaf Putri** dengan judul "Gambaran Interaksi Obat pada Pasien Rawat Jalan Penyakit Jantung Koroner di Rumah Sakit PKU Muhammadiyah Gombong Tahun 2023", bersama ini kami sampaikan bahwa pada prinsipnya kami dapat memenuhi permohonan tersebut dengan ketentuan sebagai berikut :

1. Diminta untuk berkoordinasi dengan Diklat RS
2. Menyerahkan foto ukuran 3 x 4 (2 lembar)
3. Bersedia membuat kesanggupan yang disediakan RS
4. Institusi bersedia mengganti kerugian atas kerusakan barang/alat akibat kelalaian dalam melaksanakan penelitian di RS
5. Biaya Penelitian Rp. 250.000,00
6. Waktu penelitian tanggal 27 Mei – 27 Juni 2024

Demikian kami sampaikan atas perhatiannya kami ucapkan terima kasih.

Wassalamu'alaikum warahmatullaahi wa barakaatuh.

Direktur SDI, AIK dan Umum,

dr. Rahmatwati, Sp.KJ, M.Kes
NIP. 352/11.09.1

"Melayani dengan Profesional, Ramah, Santun dan Islami"

Lampiran 3. Surat Pernyataan Lolos Etik Penelitian



KOMISI ETIK PENELITIAN KESEHATAN
HEALTH RESEARCH ETHICS COMMITTEE
UNIVERSITAS MUHAMMADIYAH GOMBONG
UNIVERSITAS MUHAMMADIYAH GOMBONG

eCertificate

KETERANGAN LAYAK ETIK
DESCRIPTION OF ETHICAL
EXEMPTION
"ETHICAL EXEMPTION"

Nomor : 117.6/II.3.AU/F/KEPK/VI/2024

No. Protokol : 11113000913



Peneliti
Researcher

: Karina Afaf Putri

Nama Institusi
Name of The Institution

: KEPK Universitas Muhammadiyah Gombong

"GAMBARAN INTERAKSI OBAT PADA PASIEN RAWAT
JALAN PENYAKIT JANTUNG KORONER DI RUMAH
SAKIT PKU MUHAMMADIYAH GOMBONG TAHUN 2023"

"OVERVIEW OF DRUG INTERACTIONS IN CORONARY
HEART DISEASE OUTPATIENTS AT PKU
MUHAMMADIYAH GOMBONG HOSPITAL IN 2023"

Dinyatakan layak etik sesuai 7 (tujuh) Standar WHO 2011, yaitu 1) Nilai Sosial, 2) Nilai Ilmiah, 3) Pemerataan Beban dan Manfaat, 4) Risiko, 5) Bujukan/Eksploitasi, 6) Kerahasiaan dan Privacy, dan 7) Persetujuan Setelah Penjelasan, yang merujuk pada Pedoman CIOMS 2016. Hal ini seperti yang ditunjukkan oleh terpenuhinya indikator setiap standar.

Declared to be ethically appropriate in accordance to 7 (seven) WHO 2011 Standards, 1) Social Values, 2) Scientific Values, 3) Equitable Assessment and Benefits, 4) Risks, 5) Persuasion/Exploitation, 6) Confidentiality and Privacy, and 7) Informed Consent, referring to the 2016 CIOMS Guidelines. This is as indicated by the fulfillment of the indicators of each standard.

Pernyataan Laik Etik ini berlaku selama kurun waktu tanggal 20 Mei 2024 sampai dengan tanggal 20 Agustus 2024

This declaration of ethics applies during the period May 20, 2024 until August 20, 2024

May 20, 2024
Professor and Chairperson,



Ning Iswati, M.Kep

Lampiran 4. Lembar Bebas Plagiarisme

	UNIVERSITAS MUHAMMADIYAH GOMBONG PERPUSTAKAAN Jl. Yos Sudarso No. 461, Telp./Fax. (0287) 472433 GOMBONG, 54412 Website : https://library.unimugo.ac.id/ E-mail : lib.unimugo@gmail.com
---	---

SURAT PERNYATAAN CEK SIMILARITY/PLAGIASI

Yang bertanda tangan di bawah ini:

Nama : Sawiji, M.Sc
NIK : 96009
Jabatan : Kepala UPT Perpustakaan, Multimedia, SIM, dan IT

Menyatakan bahwa karya tulis di bawah ini **sudah lolos** uji cek similarity/plagiasi:

Judul : Gambaran Interaksi Obat Pada Pasien Rawat Jalan Penyakit Jantung Koroner Di
RS PKU Muhammadiyah Gombong Tahun 2023.

Nama : Karina Afaf Putri
NIM : C12020025
Program Studi : S1 Farmasi
Hasil Cek : 23 %

Gombong, 6 Agustus 2024

Pustakawan


(Desy Setiyawati, M.A...)

Mengetahui,
Kepala UPT Perpustakaan, Multimedia, SIM, dan IT


(Sawiji, M.Sc)

Lampiran 5. Lembar Kegiatan Bimbingan Skripsi

	UNIVERSITAS MUHAMMADIYAH GOMBONG	Nomor	
		Revisi ke	
		Tgl. Terbit	
		Halaman	

Nama mahasiswa : KARUNA ARAF PUTRA
 NIM : 612020025
 Pembimbing : apt. Chondowati Mayoris, M.clin, Pharm

Tanggal Bimbingan	Topik/Materi bimbingan	Paraf Mahasiswa	Paraf pembimbing
12 Oktober 2023	berkultasi dasar proposal		
18 Desember 2023	berkultasi Bab 1, 2, 3		
21 Desember 2023	berkultasi Bab 1, 2, 3		
8 Januari 2024	berkultasi Bab 1, 2, 3		
13 Januari 2024	Acc proposal		

Gombong, 13 Januari 2024
 Mengetahui
 Kepala Program Studi

 Apt. Naclaz Zukhruf WK, M.Pharm.Sci

	UNIVERSITAS MUHAMMADIYAH GOMBONG	Nomor	: PDN-SKP/12/005
		Revisi ke	: 02
		Tgl. Terbit	18 Agustus 2020
		Halaman	

Nama mahasiswa : KARINA ARAF PUSRI
NIM : 619020025
Pembimbing : apt. Chondrogoro Nuryono, M. clini. Pharm

Tanggal Bimbingan	Topik/Materi Bimbingan	Paraf Mahasiswa	Paraf Pembimbing
8 Juni 2024	Bimbingan batu	Juf	Juf
16 Juli 2024	Bimbingan Hasil analisis batu	Juf	Juf
20 Juli 2024	Bimbingan Bab 1-5	Juf	Juf
23 Juli 2024	Bimbingan Revisi: Bab 1-5	Juf	Juf
29 Juli 2024	Bimbingan Revisi abstrak	Juf	Juf
30 Juli 2024	Acc Masbuh Skripsi	Juf	Juf


Gombong, 02 Bulan 08 Tahun 2024

Mengetahui
Ketua Program Studi Farmasi
apt. Naelaz Zulkhruf WK, M. Pharm. Sci
NIDN:



Nomor	: PDN-SKP/12/005
Revisi ke	: 02
Tgl. Terbit	18 Agustus 2020
Halaman	

Nama mahasiswa : KARINA ARAF PUTRI
NIM : 210200025
Pembimbing : apt. ANWAR Shodik, M. Farm

Tanggal Bimbingan	Topik/Materi Bimbingan	Paraf Mahasiswa	Paraf Pembimbing
4 oktober 2023	konsep dan judul proposal	Juf	
23 oktober 2023	acc judul proposal	Juf	
11 Januari 2024	konultasi Bab 1, 2, 3	Juf	
20 Januari 2024	konultasi Bab 1, 2, 3	Juf	
25 Januari 2024	konultasi Bab 1, 2, 3	Juf	
25 Januari 2024	acc proposal	Juf	

Gombong, 25 Bulan 01 Tahun 2029

Mengetahui
Ketua Program Studi Farmasi

Apt. Naelaz Zukhruf WK, M.Pharm.Sci




	UNIVERSITAS MUHAMMADIYAH GOMBONG	Nomor	: PDN-SKP/12/005
		Revisi ke	: 02
		Tgl. Terbit	: 18 Agustus 2020
		Halaman	

Nama mahasiswa : KARIMA AFAR PUTRA
 NIM : C12020025
 Pembimbing : apik Anwar Sodik, Nrl. Faim

Tanggal Bimbingan	Topik/Materi Bimbingan	Paraf Mahasiswa	Paraf Pembimbing
9 Juni 2024	Bimbingan Duku.	Juf	
17 Juli 2024	Bimbingan Hasil Analisis Duku.	Juf	
18 Juli 2024	Bimbingan Bab 1-5	Juf	
20 Juli 2024	Bimbingan Review Bab 1-5	Juf	
31 Juli 2024	Bimbingan abstrak, bab 1-5	Juf	
1 Agustus 2024	Bimbingan keuni abstrak, bab 1-5	Juf	
2 Agustus 2024	Acc Naskah Skripsi.	Juf	

Gombong, 02... Bulan 08... Tahun 2024


 Mengetahui
 Ketua Program Studi Farmasi

 apt. Naclan Z. Khuruf WK, M.Pharm.Sci
 NIDN 12020025

Lampiran 6. Data Obat Yang Berinteraksi dan Tingkat Keparahan Interaksi Obat

No	Kombinasi yang berpotensi	Interaksi Obat	Mekanisme	Jumlah	Persentase (%)
1	Alprazolam + Digoxin	<i>Monitor Closely / Moderat</i>	Farmakodinamik	1	0,13%
2	Amiodarone + Ondancetron	Serius / Mayor	Tidak diketahui	1	0,13%
3	Amiodarone + Bisoprolol	<i>Monitor Closely / Moderat</i>	Farmakodinamik Sinergis	1	0,13%
4	Amlodipine + Bisoprolol	<i>Monitor Closely / Moderat</i>	Farmakodinamik Sinergis	4	0,50%
5	Amlodipine + Metformin	<i>Monitor Closely / Moderat</i>	Farmakodinamik Antagonis	4	0,50%
6	Amlodipine + Nifedipine	<i>Monitor Closely / Moderat</i>	Tidak diketahui	1	0,13%
7	Amlodipine + Simvastatin	Serius / Mayor	Farmakokinetik Fase Metabolisme	38	4,80%
8	Aspirin + Bisoprolol	<i>Monitor Closely / Moderat</i>	Farmakodinamik Antagonis	121	15,28%
9	Aspirin + Candesartan	<i>Monitor Closely / Moderat</i>	Farmakodinamik Antagonis	82	10,35%
10	Aspirin + Ciprofloxacin	<i>Monitor Closely / Moderat</i>	Tidak diketahui	3	0,38%
11	Aspirin + Clopidogrel	<i>Monitor Closely / Moderat</i>	Farmakodinamik Sinergis	13	1,64%
12	Aspirin + Digoxin	<i>Monitor Closely / Moderat</i>	Farmakokinetik Fase Ekresi	1	0,13%
13	Aspirin + Furosemide	Minor	Farmakodinamik sinergis	41	5,17%
14	Aspirin + Insulin Aspart	<i>Monitor Closely / Moderat</i>	Farmakodinamik Sinergis	2	0,25%

15	Aspirin + Irbesartan	<i>Monitor Closely / Moderat</i>	Farmakodinamik Antagonis	16	2,02%
16	Aspirin + Mecobalamin	Minor	Tidak diketahui	5	0,63%
17	Aspirin + Ramipril	Serius / Mayor	Farmakodinamik Antagonis	2	0,25%
18	Aspirin + Sacubitril/Valsartan (Uperio)	<i>Monitor Closely / Moderat</i>	Farmakodinamik Antagonis	8	1,01%
19	Aspirin + Spironolactone	<i>Monitor Closely / Moderat</i>	Tidak diketahui	14	1,77%
20	Aspirin + Valsartan	<i>Monitor Closely / Moderat</i>	Farmakodinamik Antagonis	2	0,25%
21	Atorvastatin + Digoxin	<i>Monitor Closely / Moderat</i>	Farmakokinetik Fase Eksresi	4	0,50%
22	Atorvastatin + Valsartan	<i>Monitor Closely / Moderat</i>	Farmakodinamik	2	0,25%
23	Bisoprolol + Amlodipine	<i>Monitor Closely / Moderat</i>	Farmakodinamik Sinergis	32	4,04%
24	Bisoprolol + Candesartan	<i>Monitor Closely / Moderat</i>	Farmakodinamik Sinergis	112	14,14%
25	Bisoprolol + Digoxin	<i>Monitor Closely / Moderat</i>	Farmakodinamik Sinergis	3	0,37%
26	Bisoprolol + Furosemide	<i>Monitor Closely / Moderat</i>	Farmakodinamik Antagonis	42	5,30%
27	Bisoprolol + HCT	<i>Monitor Closely / Moderat</i>	Farmakodinamik Sinergis	2	0,25%
28	Bisoprolol + Irbesartan	<i>Monitor Closely / Moderat</i>	Farmakodinamik Sinergis	15	1,89%
29	Bisoprolol + Nifedipine	<i>Monitor Closely / Moderat</i>	Farmakodinamik Sinergis	3	0,38%
30	Bisoprolol + Sacubitril/Valsartan (Uperio)	<i>Monitor Closely / Moderat</i>	Farmakodinamik Sinergis	6	0,76%

31	Bisoprolol + Spironolactone	<i>Monitor Closely / Moderat</i>	Farmakodinamik Sinergis	20	2,52%
32	Bisoprolol + Valsartan	<i>Monitor Closely / Moderat</i>	Farmakodinamik Sinergis	4	0,50%
33	Candesartan + Aspirin	<i>Monitor Closely / Moderat</i>	Farmakodinamik Antagonis	2	0,25%
34	Candesartan + Digoxin	<i>Monitor Closely / Moderat</i>	Tidak diketahui	1	0,13%
35	Candesartan + Furosemide	<i>Monitor Closely / Moderat</i>	Farmakodinamik Antagonis	17	2,15%
36	Candesartan + Insulin Aspart	<i>Monitor Closely / Moderat</i>	Tidak diketahui	2	0,25%
37	Candesartan + Insulin Glargine	<i>Monitor Closely / Moderat</i>	Tidak diketahui	1	0,13%
38	Candesartan + Insulin Lispro	<i>Monitor Closely / Moderat</i>	Tidak diketahui	1	0,13%
39	Candesartan + Meloxicam	<i>Monitor Closely / Moderat</i>	Farmakodinamik antagonis	2	0,25%
40	Candesartan + Spironolactone	<i>Monitor Closely / Moderat</i>	Farmakodinamik	6	0,76%
41	Cefixime + Furosemide	Minor	Farmakodinamik Sinergis	2	0,25%
42	Ciprofloxacin + Alprazolam	Minor	Tidak diketahui	1	0,13%
43	Clonidine - Bisoprolol	Serius / Mayor	Farmakodinamik sinergis	2	0,25%
44	Clopidogrel + Meloxicam	<i>Monitor Closely / Moderat</i>	Farmakodinamik Sinergis	2	0,25%
45	Digoxin + Bisoprolol	Serius / Mayor	Tidak diketahui	4	0,50%
46	Digoxin + Metformin	<i>Monitor Closely / Moderat</i>	Tidak diketahui	1	0,13%

47	Fenofibrate + Atorvastatin	Serius / Mayor	Farmakodinamik Sinergis	1	0,13%
48	Fenofibrate + Insulin Glargine	<i>Monitor Closely / Moderat</i>	Tidak diketahui	1	0,13%
49	Fenofibrate + Insulin Lispro	<i>Monitor Closely / Moderat</i>	Tidak diketahui	1	0,13%
50	Furosemide + Digoxin	<i>Monitor Closely / Moderat</i>	Farmakodinamik Sinergis	4	0,50%
51	Furosemide + HCT	<i>Monitor Closely / Moderat</i>	Farmakodinamik	4	0,50%
52	Furosemide + Metformin	Minor	Farmakodinamik Antagonis	7	0,88%
53	Gemfibrozil + Atorvastatin	Serius / Mayor	Farmakodinamik Sinergis	1	0,13%
54	Gemfibrozil + Insulin Glargine	<i>Monitor Closely / Moderat</i>	Tidak diketahui	1	0,13%
55	Gemfibrozil + Insulin Lispro	<i>Monitor Closely / Moderat</i>	Tidak diketahui	1	0,13%
56	HCT + Metformin	Minor	Farmakodinamik Antagonis	2	0,25%
57	HCT + Glimepiride	Minor	Farmakodinamik antagonis	2	0,25%
58	Ibuprofen + Bisoprolol	<i>Monitor Closely / Moderat</i>	Farmakodinamik Antagonis	2	0,25%
59	Ibuprofen + Candesartan	<i>Monitor Closely / Moderat</i>	Farmakodinamik Antagonis	2	0,25%
60	Irbesartan + aspirin	<i>Monitor Closely / Moderat</i>	Farmakodinamik Antagonis	1	0,13%
61	Irbesartan + Digoxin	<i>Monitor Closely / Moderat</i>	Tidak diketahui	1	0,13%
62	Irbesartan + Furosemide	<i>Monitor Closely / Moderat</i>	Tidak diketahui	9	1,14%
63	Ketorolac + Gentamicin	Minor	Tidak diketahui	1	0,13%

64	Lansoprazole + Clopidogrel	<i>Monitor Closely / Moderat</i>	Farmakokinetik Fase Metabolisme	17	2,15%
65	Lansoprazole + Mecobalamin	Minor	Tidak diketahui	5	0,63%
66	Meloxicam + Bisoprolol	<i>Monitor Closely / Moderat</i>	Tidak diketahui	1	0,13%
67	Moeloxicam + Furosemide	Minor	Farmakodinamik	1	0,13%
68	Metformin + Furosemide	Minor	farmakodinamik antagonis	8	1,01%
69	Metformin + Mecobalamin	Minor	Tidak diketahui	4	0,50%
70	Metronidazole + Paracetamol	Minor	Tidak diketahui	1	0,13%
71	Nifedipine + Amlodipine	Serius / Mayor	Farmakodinamik Antagonis	2	0,25%
72	Nifedipine + Atorvastatin	<i>Monitor Closely / Moderat</i>	Farmakokinetik Fase Metabolisme	1	0,13%
73	Nifedipine + Metformin	<i>Monitor Closely / Moderat</i>	Farmakodinamik Antagonis	1	0,13%
74	Nifedipine + Simvastatin	Serius / Mayor	Farmakodinamik Antagonis	3	0,38%
75	Omeprazole + Clopidogrel	Serius / Mayor	Farmakokinetik Fase Metabolisme	1	0,13%
76	Ramipril + Metformin	<i>Monitor Closely / Moderat</i>	Farmakodinamik Antagonis	3	0,38%
77	Ramipril + Spironolactone	<i>Monitor Closely / Moderat</i>	Farmakodinamik Sinergis	2	0,25%
78	Sacubitril/Valsartan (Uperio) + Simva	Minor	Tidak diketahui	1	0,13%
79	Sacubitril/Valsartan (Uperio) + Trimethopim	<i>Monitor Closely / Moderat</i>	Tidak diketahui	1	0,13%
80	Simvastatin + Atorvastatin	<i>Monitor Closely / Moderat</i>	Farmakodinamik Sinergis	2	0,25%

81	Simvastatin + Digoxin	<i>Monitor Closely / Moderat</i>	Tidak diketahui	3	0,38%
82	Simvastatin + Sacubitril/Valsartan (Uperio)	<i>Monitor Closely / Moderat</i>	Tidak diketahui	9	1,14%
83	Simvastatin + Valsartan	<i>Monitor Closely / Moderat</i>	Tidak diketahui	2	0,25%
84	Spironolactone + Digoxin	<i>Monitor Closely / Moderat</i>	Farmakokinetik Fase Ekresi	6	0,76%
85	Spironolactone + Furosemide	<i>Monitor Closely / Moderat</i>	Tidak diketahui	20	2,53%
86	Spironolactone + HCT	<i>Monitor Closely / Moderat</i>	Tidak diketahui	2	0,25%
87	Spironolactone + Potassium Chloride	Serius / Mayor	Tidak diketahui	2	0,25%
88	Sucralfate + Lansoprazole	Minor	Farmakokinetik	2	0,25%
89	Valsartan + Furosemide	<i>Monitor Closely / Moderat</i>	Farmakodinamik	2	0,25%
Total				792	100,00%

Lampiran 7. Lembar Pengumpulan Data

No	Nama pasien	Jenis kelamin	Usia	Diagnose	Obat yang diberikan	Interaksi obat					
						Medscape			Drugs. Com		
						Obat yang berinteraksi	Tingkat keparahan	Mekanisme	Obat yang berinteraksi	Tingkat keparahan	Mekanisme
1	Tn. PTN	L	55 Th	CAD, Hipertensi, Iskalgia	Amlodipine Sanmagh Neurodex Azytromicin Metronidazole Paracetamol Gentamicin Ketorolac Ceftriaxone	Ketorolac – Gentamicin Metronidazole – paracetamol	Minor Minor		Gentamicin – ceftriaxone Ketorolac – amlodipine Gentamicin – ketorolac Azitromicin – metronidazole	Moderat Moderat Moderat Moderat	
2	Ny. SWT	P	50 th	CHF + Hipertensi	Amlodipine Bisoprolol Miniaspi (aspirin) Alprazolam Simvastatin Adalat Oros (nifedipine)	Nifedipine – amlodipine Nifedipine – simvastatin Amlodipine – simvastatin	Serius Serius Serius		Amlodipine – simvastatin Nifedipine – alprazolam Amlodipine – bisoprolol Aspirin – bisoprolol	Mayor Moderat Moderat Minor	

3	Tn. NRN	L	50 th	Dislipidemi a CHF	Fenofibrate Bisoprolol Adalat Oros (nifedipine) Amlodipine Lansoprazole	Nifedipine – amlodipine Bisoprolol – nifedipine Bisoprolol – amlodipine Amlodipine – nifedipine	Serius <i>Monitor Closely / Moderat</i>		Nifedipine – bisoprolol Amlodipine – bisoprolol Lansoprazole – fenofibrate	Moderat Moderat Moderat	
4	Tn. SWO	L	55 th	CHF GGA	Spironolactone Miniaspi Simvastatin Digoxin ISDN Candesartan Bisoprolol Alprazolam	Digoxin – bisoprolol Aspirin – spironolactone Candesartan – aspirin Spironolactone – digoxin	Mayor <i>Monitor Closely / Moderat Monitor Closely / Moderat</i>		Spironolactone – candesartan Alprazolam – digoxin Aspirin – spironolactone Aspirin – bisoprolol	Mayor Moderat Minor Minor	
5	Ny. SMH	P	41 th	CHF + Hipertensi	Furosemide Ranitidine Ondansetron Amlodipine Amiodaron	Amiodaron – ondansetron	Serius		Amiodaron – furosemide Amiodaron – ondansetron	Mayor	

6	Ny.D IS	P	57 th	CAD	Spironolactone Digoxin Simvastatin ISDN	Simvastatin – digoxin Spironolactone – digoxin	<i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i>	simvastatin akan meningkatkan kadar atau efek digoksin	Digoxin – spironolactone	Moderat	
7	Tn. ABD	L	58 th	CHF + Hipertensi	Valisanbe (diazepam) Bisoprolol Candesartan Meloxicam Alprazolam Furosemide	Meloxicam – furosemide Bisoprolol – candesartan Meloxicam – bisoprolol	Minor Monitor closely / Moderat	Farmakodinamik Farmakodinamik sinergis	Furosemide – bisoprolol Alprazolam – bisoprolol	Moderat Moderat	
8	Ny. ES	P	58 th	HHD VAP Dislipidemia	Atorvastatin Concor (Bisoprolol) Spironolactone Furosemide Aspilet	Aspirin – bisoprolol Aspirin – furosemide	<i>Monitor Closely / Moderat</i> Minor	Farmakodinamik antagonis Farmakodinamik antagonis	Furosemide – bisoprolol Spironolactone – bisoprolol Furosemide – aspirin Aspirin – bisoprolol Aspirin – spironolactone	Moderat Moderat Minor Minor Minor	

9	Ny. N	P	59 Th	CHF Dislipidemia	Simvastatin Allopurinol Mecobalamine Nospirinal Lansoprazole	Tidak ada interaksi			Simvastatin – lansoprazole Aspirin – lansoprazole	Moderat Minor	
10	Ny. D	P	59 Th	Hipertensi CHF	Simvastatin Bisoprolol Candesartan Furosemide Miniaspi	Bisoprolol – candesartan Aspirin – bisoprolol Aspirin – furosemide	<i>Monitor Closely / Moderat</i> Minor	Farmakodinamik sinergis Farmakodinamik antagonis Farmakodinamik antagonis	Furosemide – bisoprolol Aspirin – candesartan Furosemide – aspirin Aspirin - bisoprolol	Moderat Minor	
11	Tn. S	L	60 Th	CHF Stable Angina	Candesartan Lansoprazole Simvastatin Miniaspi (aspirin) Clopidogrel	Aspirin – clopidogrel Aspirin – candesartan Lansoprazole – clopidogrel	<i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i>	Farmakodinamik sinergis Farmakodinamik antagonis	Simvastatin – lansoprazole Aspirin – clopidogrel Lansoprazole – clopidogrel Aspirin – candesartan	Moderat Moderat Moderat Minor	

									Aspirin – lansoprazole		
12	Ny. T	P	58 Th	CHF Dislipidemia	Bisoprolol Braxidin (chlordiazepoxide/ clidinium) Lansoprazole Candesartan Nospirinal	Bisoprolol – candesartan Aspirin – bisoprolol	<i>Monitor Closely / Moderat</i>	Farmakodinamik sinergis Farmakodinamik antagonis	Chlordiazepoxide – bisoprolol Aspirin – candesartan Chlordiazepoxide – candesartan Aspirin – bisoprolol Aspirin – lansoprazole	Moderat Moderat Moderat Minor Minor	
13	Tn. KM	L	64 Th	HHD CHF	Beraprost Bisoprolol Candesartan Lansoprazole Simvastatin	Bisoprolol – candesartan	<i>Monitor Closely / Moderat</i>	Farmakodinamik sinergis	Simvastatin – lansoprazole	Moderat	
14	Ny. NMS	P	43 Th	Angina Pectoris Stable Hipertensi	Alprazolam Nospirinal (aspirin) Lansoprazole Simvastatin Bisoprolol	Bisoprolol – candesartan Aspirin – bisoprolol Aspirin – candesartan	<i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i>	Farmakodinamik sinergis Farmakodinamik antagonis Farmakodinamik antagonis	Alprazolam – bisoprolol Simvastatin – lansoprazole	Moderat Moderat Moderat Moderat	

					Candesartan				Alprazolam – candesartan Aspirin – candesartan Aspirin – bisoprolol Aspirin – lansoprazole	Minor Minor	
15	Ny. DMA	P	41 Th	CHF Hipertensi	Miniaspi (aspirin) Simvastatin Candesartan Amlodipin	Amlodipine – simvastatin Candesartan – aspirin	Serius <i>Monitor Closely / Moderat</i>	Farmakodinamik antagonis	Amlodipine – simvastatin Aspirin – amlodipine Aspirin – candesartan	Mayor Moderat	
16	Ny. B	P	67 Th	CHF Chepalgia	Nospirinal (aspirin) Candesartan Bisoprolol Simvastatin Allopurinol	Bisoprolol – candesartan Aspirin – bisoprolol Aspirin – candesartan	<i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i>	Farmakodinamik sinergis Farmakodinamik antagonis Farmakodinamik antagonis	Aspirin – candesartan Aspirin – bisoprolol	Moderat Minor	
17	Tn. RS	L	64 Th	CHF IHD	Cefixime Bisoprolol Candesartan Simvastatin	Bisoprolol – candesartan	<i>Monitor Closely / Moderat</i> Minor	Farmakodinamik sinergis	Furosemide – cefixime	Moderat Moderat	

					Furosemide	Cefixime – furosemide		Farmakodinam ik sineergis	Furosemide – bisoprolol		
18	Ny. SNM	P	63 Th	CHF Hipertensi	Miniaspi (aspirin) Simvastatin Amlodipin Bisoprolol	Amlodipine – simvastatin Bisoprolol – amlodipine Aspirin – bisoprolol	Serius <i>Monitor Closely / Moderat</i>	Farmakodinam ik sinergis Farmakodinam ik antagonis	Amlodipine – simvastatin Aspirin – amlodipine Amlodipine – bisoprolol Aspirin – bisoprolol	Mayor Moderat Moderat Minor	
19	Ny. K	P	64 Th	IHD Hipokalemi a	CPG (clopidogrel) Concor (bisoprolol) Candesartan Amlodipin Furosemide	Bisoprolol – candesartan Bisoprolol – amlodipine Candesartan – furosemide	<i>Monitor Closely / Moderat Monitor Closely / Moderat</i>	Farmakodinam ik sinergis Farmakodinam ik sinergis	Furosemide – bisoprolol Amlodipine – bisoprolol	Moderat Moderat	
20	Tn. M	L	63 Th	IHD Hiperkalemi a	Nitrokaf retard (nitrogliserin) Miniaspi (aspirin) Simvastatin	Bisoprolol – candesartan Aspirin – bisoprolol Aspirin – candesartan	<i>Monitor Closely / Moderat Monitor Closely / Moderat</i>	Farmakodinam ik sinergis Farmakodinam ik antagonis Farmakodinam ik antagonis	Furosemide – bisoprolol Aspirin – candesartan Furosemide – aspirin	Moderat Moderat Minor	

					Candesartan Bisoprolol Furosemide	Aspirin – furosemide	Minor	Farmakodinam ik antagonis	Aspirin – nitrogliserin Aspirin – bisoprolol	Minor Minor	
21	Ny. Y	P	56 Th	CHF IHD	Furosemide Simvastatin Miniaspi (aspirin) Candesartan Bisoprolol Alprazolam	Bisoprolol – candesartan Aspirin – bisoprolol Aspirin – candesartan Aspirin – furosemide	<i>Monitor Closely / Moderat Monitor Closely / Moderat</i> Minor	Farmakodinam ik sinergis Farmakodinam ik antagonis Farmakodinam ik antagonis Farmakodinam ik antagonis	Furosemide – alprazolam Furosemide – bisoprolol Alprazolam – bisoprolol Alprazolam – candesartan Aspirin candesartan Furosemide – aspirin Aspirin – bisoprolol	Moderat Moderat Moderat Moderat Moderat Minor Minor	
22	Tn. A	L	62 Th	CHF Chepalgia DM	Metformin Simvastatin Bisoprolol Nospirinal (aspirin) Candesartan Lansoprazol e	Bisoprolol – candesartan Aspirin – bisoprolol Aspirin – candesartan	<i>Monitor Closely / Moderat Monitor Closely / Moderat</i>	Farmakodinam ik sinergis Farmakodinam ik antagonis Farmakodinam ik antagonis	Simvastatin – lansoprazole Aspirin – candesartan Aspirin – bisoprolol	Moderat Moderat Minor Minor	

									Aspirin – lansoprazole		
23	Ny. A	P	63 Th	CHF	Beraprost Miniaspi (aspirin) Bisoprolol Lansoprazole Allopurinol Atorvastatin	Aspirin – bisoprolol	<i>Monitor Closely / Moderat</i>	Farmakodinamik antagonis	Lansoprazole – atorvastatin Aspirin – bisoprolol Aspirin – lansoprazole	Moderat Minor Minor	
24	Ny. R	P	61 Th	CHF	Lansoprazole Simvastatin Bisoprolol Candesartan Nospirinal (aspirin)	Bisoprolol – candesartan Aspirin – bisoprolol Aspirin – candesartan	<i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i>	Farmakodinamik sinergis Farmakodinamik antagonis Farmakodinamik antagonis	Simvastatin – lansoprazole Aspirin – candesartan Aspirin – bisoprolol Aspirin – lansoprazole	Moderat Moderat Minor Minor	
25	Ny. EP	P	47 Th	Aritmia CHF	Furosemide Lapisiv Lansoprazole Simvastatin Candesartan Bisoprolol	Bisoprolol – candesartan Bisoprolol – furosemide Candesartan – furosemide	<i>Monitor Closely / Moderat</i> Monitor closely / Moderat	Farmakodinamik sinergis	Furosemide – bisoprolol Furosemide – lansoprazole	Moderat Moderat Moderat	

							<i>Monitor Closely / Moderat</i>		Simvastatin – lansoprazole		
26	Ny. SS	P	40 Th	Aritmia Hipokalemi a CHF	Nospirinal (aspirin) Bisoprolol Lansoprazole Concor	Aspirin – bisoprolol	<i>Monitor Closely / Moderat</i>	Farmakodinamik antagonis	Aspirin – bisoprolol Aspirin – lansoprazole	Minor Minor	
27	Tn. Y	L	55 Th	IHD CHF	Nitrokaf retard (nitrogliserin) Simvastatin Bisoprolol Miniaspi (aspirin) Candesartan Beraprost	Bisoprolol – candesartan Aspirin – bisoprolol Aspirin – candesartan	<i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i>	Farmakodinamik sinergis Farmakodinamik antagonis Farmakodinamik antagonis	Aspirin – candesartan Aspirin – nitrogliserin Aspirin – bisoprolol	Moderat Minor Minor	
28	Tn. S	L	56 Th	CHF	Uresix (furosemide) Simvastatin Lansoprazole Nospirinal (aspirin)	Aspirin – furosemide Aspirin – furosemide	<i>Monitor Closely / Moderat</i> Minor	 Farmakodinamik antagonis	Furosemide – lansoprazole Simvastatin – lansoprazole	Moderat Moderat Minor Minor	

									Furosemide – aspirin Aspirin – lansoprazole		
29	Ny. N	P	62 Th	CHF Hipertensi	Lansoprazol e Amlodipin Bisoprolol Candesartan Simvastatin	Amlodipine – simvastatin Bisoprolol – amlodipine Bisoprolol – candesartan	Serius <i>Monitor Closely / Moderat</i>	Farmakodinam ik sinergis Farmakodinam ik sinergis	Amlodipine – simvastatin Amlodipine – bisoprolol Simvastatin – lansoprazole	Mayor Moderat Moderat	
30	Tn. S	L	64 Th	CAD DM	Glibenklami de Metformin Bisoprolol Atorvastatin Mecobalami n	Tidak ada interaksi			Glyburide / metformin – bisoprolol	Moderat	
31	Tn. D	L	72 Th	CAD Stable Angina CHF	CPG (clopidogrel) Amlodipin Candesartan Bisoprolol Simvastatin ISDN	Amlodipine – simvastatin Bisoprolol – amlodipine Bisoprolol – candesartan	Serius / mayor <i>Monitor Closely / Moderat</i>	Farmakodinam ik sinergis Farmakodinam ik sinergis	Amlodipine – simvastatin Amlodipine – bisoprolol	Mayor Moderat Moderat Moderat	

					Lansoprazol e	Lansoprazol e – clopidogrel	<i>Monitor Closely / Moderat</i>		Simvastatin – lansoprazole Lansoprazol e - clopidogrel		
32	Tn. M	L	60 Th	ACS VAP	Aspilet (aspirin) CPG (clopidogrel) Candesartan Atorvastatin Nitrokaf retard (nitrogliserin) Concor (bisoprolol) Loxadin	Bisoprolol – candesartan Aspirin – bisoprolol Aspirin – clopidogrel Aspirin – candesartan	<i>Monitor Closely / Moderat Monitor Closely / Moderat Monitor Closely / Moderat Monitor Closely / Moderat</i>	Farmakodinam ik sinergis Farmakodinam ik antagonis Farmakodinam ik sinergis Farmakodinam ik antagonis	Aspirin – clopidogrel Atorvastatin – clopidogrel Aspirin – candesartan Aspirin – nitroglicerine Aspirin – bisoprolol	Moderat Moderat Moderat Minor Minor	
33	Tn. TS	L	58 Th	CHF	Atorvastatin Allopurinol Nitrokaf retard (nitroglicerine) Meloxicam Candesartan Clopidogrel	Candesartan – meloxicam Clopidogrel – meloxicam Atorvastatin – digoxin	<i>Monitor Closely / Moderat Monitor Closely / Moderat Monitor Closely / Moderat</i>	Farmakodinam ik antagonis Farmakodinam ik sinergis	Candesartan – meloxicam Digoxin – atorvastatin Atorvastatin – clopidogrel Digoxin – meloxicam	Moderat Moderat Moderat Moderat	

					Digoxin				Clopidogrel – meloxicam	Moderat	
34	Ny. M	P	48 Th	IHD CHF Hipertensi	Aspirin Amlodipin CPG (clopidogrel) Bisoprolol Candesartan ISDN Lansoprazole	Aspirin – clopidogrel Aspirin – candesartan Lansoprazole – clopidogrel	<i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i>	Farmakodinamik sinergis Farmakodinamik antagonis	Aspirin – amlodipine Aspirin – clopidogrel Aspirin – candesartan Lansoprazole – clopidogrel Aspirin – lansoprazole	Moderat Moderat Moderat Moderat Minor	
35	Ny. MS	P	50 Th	IHD CHF	Nospirinal (aspirin) Simvastatin Bisoprolol Nitrokaf retard (nitroglicerine) Allopurinol	Aspirin – bisoprolol	<i>Monitor Closely / Moderat</i>	Farmakodinamik antagonis	Aspirin – bisoprolol Aspirin – nitroglicerine	Minor Minor	
36	Ny. SA	P	45 Th	IHD CHF	Nitrokaf retard (nitroglicerine)	Aspirin – bisoprolol Aspirin – spironolactone	<i>Monitor Closely / Moderat</i>	Farmakodinamik antagonis	Spironolactone – bisoprolol	Moderat Minor	

					Miniaspi (aspirin) Bisoprolol Spironolaktone Simvastatin	Bisoprolol – spironolactone	<i>Monitor Closely / Moderat</i>		Aspirin – spironolactone Aspirin – nitroglycerin Aspirin – bisoprolol	Minor Minor	
37	Ny. R	P	77 Th	CHF IHD Hipertensi	Irbesartan Amlodipine Simvastatin Allopurinol Nospirinal (aspirin) Bisoprolol	Amlodipine – simvastatin Bisoprolol – amlodipine Irbesartan – aspirin Bisoprolol – irbesartan Aspirin – bisoprolol	Serius / mayor <i>Monitor Closely / Moderat Monitor Closely / Moderat Monitor Closely / Moderat</i>	Farmakodinamik sinergis Farmakodinamik antagonis Farmakodinamik sinergis Farmakodinamik antagonis	Amlodipine – simvastatin Aspirin – amlodipine Amlodipine – bisoprolol Aspirin – irbesartan Aspirin – bisoprolol	Mayor Moderat Moderat Moderat Minor	
38	Tn. R	L	65 Th	IHD CHF	Miniaspi (aspirin) Candesartan Bisoprolol Alprazolam Simvastatin	Bisoprolol – candesartan Aspirin – bisoprolol Aspirin – candesartan	<i>Monitor Closely / Moderat Monitor Closely / Moderat</i>	Farmakodinamik sinergis Farmakodinamik antagonis Farmakodinamik antagonis	Alprazolam – bisoprolol Alprazolam – candesartan Aspirin – candesartan	Moderat Moderat Moderat Minor	

									Aspirin – bisoprolol		
39	Ny. S	P	60 Th	CHF CKD DM	Aspilet (aspirin) CPG (clopidogrel) ISDN Irbesartan Amlodipine Digoxin Nospirinal (aspirin)	Aspirin – clopidogrel Aspirin – irbesartan Irbesartan – digoxin	<i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i>	Farmakodinamik sinergis Farmakodinamik antagonis	Aspirin – digoxin Aspirin – amlodipine Aspirin – irbesartan Aspirin – clopidogrel	Moderat Moderat Moderat Moderat	
40	Tn. YA	L	61 Th	CHF CAD DM	Aspilet (aspirin) CPG (clopidogrel) Concor (bisoprolol) Candesartan Simvastatin ISDN Metformin	Bisoprolol – candesartan Aspirin – bisoprolol Aspirin – clopidogrel Aspirin – candesartan	<i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i>	Farmakodinamik sinergis Farmakodinamik antagonis Farmakodinamik sinergis Farmakodinamik antagonis	Aspirin – clopidogrel Aspirin – candesartan Aspirin – bisoprolol	Moderat Moderat Minor	
41	Ny. SM	P	76 Th	CHF	Mecobalamine Sucralfate KSR (potassium chloride)	Spironolactone – potassium chloride	Serius / mayor Monitor closely		Spironolactone – potassium chloride	Mayor Moderat	

					Spirolakto ne Lansoprazol e Simvastatin CPG (clopidogrel)	Lansoprazol e – clopidogrel Sucralfate – lansoprazole	Minor		Sucralfate – lansoprazole Simvastatin – lansoprazole Lansoprazol e – clopidogrel	Moderat Moderat	
42	Ny. SS	P	43 Th	CHF	Nospirinal (aspirin) Simvastatin Candesartan Bisoprolol	Bisoprolol – candesartan Aspirin – bisoprolol Aspirin – candesartan	<i>Monitor Closely / Moderat Monitor Closely / Moderat</i>	Farmakodinam ik sinergis Farmakodinam ik antagonis Farmakodinam ik antagonis	Aspirin – candesartan Aspirin – bisoprolol	Moderat Minor	
43	Tn. S	L	59 Th	CHF Hipertensi	Alprazolam Nitrokaf retard (nitroglicer in) Lansoprazol e Miniaspi (aspirin) Bisoprolol Spirolacton e	Aspirin – bisoprolol Aspirin – spironolacton e	<i>Monitor Closely / Moderat</i>	Farmakodinam ik antagonis	Alprazolam – nitroglicer in Alprazolam – spironalcton e Alprazolam – bisoprolol Spirolacton e – bisoprolol	Moderat Moderat Moderat Minor Minor	

									Aspirin – nitroglicerine Aspirin – spironolactone Aspirin – bisoprolol Aspirin – lansoprazole	Minor Minor	
44	Tn. IW	L	67 Th	CHF	Gemfibrozil Nospirinal (aspirin) Bisoprolol Alprazolam Nitrokaf retard (nitroglicerine)	Aspirin – bisoprolol	<i>Monitor Closely / Moderat</i>	Farmakodinamik antagonis	Alprazolam – nitroglicerine Alprazolam – bisoprolol Aspirin – nitroglicerine Aspirin – bisoprolol	Moderat Moderat Minor Minor	
45	Ny. M	P	68 Th	CHF Hipertensi	Farsifent (ibuprofen) Candesartan Amlodipine Bisoprolol Simvastatin Allopurinol	Amlodipine – simvastatin Bisoprolol – amlodipine Bisoprolol – candesartan Ibuprofen – bisoprolol	Serius / mayor <i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i>	 Farmakodinamik sinergis Farmakodinamik sinergis Farmakodinamik antagonis	Amlodipine – simvastatin Ibuprofen – amlodipine Ibuprofen – bisoprolol	Mayor Moderat Moderat Moderat	

						Ibuprofen – candesartan	<i>Monitor Closely / Moderat</i>	Farmakodinam ik antagonis	Ibuprofen – candesartan Amlodipine – bisoprolol	Moderat	
46	Ny. YI	P	31 Th	CHF Pneumonia	Furosemide Spironolacto ne Bisoprolol Nitrokaf retard (nitroglicer in) Lansoprazol e	Bisoprolol – spironolacto ne Spironolacto ne – furosemide Bisoprolol – furosemide	<i>Monitor Closely / Moderat</i>		Furosemide – bisoprolol Spironolacto ne – bisoprolol Furosemide – lansoprazole	Minor Minor Minor	
47	Ny. P	P	45 Th	CHF HHD Hipokalemi a	Candesartan Amlodipine Simvastatin Bisoprolol	Amlodipine – simvastatin Amlodipine – bisoprolol Bisoprolol – candesartan	Serius / mayor <i>Monitor Closely / Moderat</i>	Farmakodinam ik sinergis Farmakodinam ik sinergis	Amlodipine – simvastatin Amlodipine – bisoprolol	Mayor Moderat	
48	Tn. PA	L	66 Th	CAD DM	Simvastatin Candesartan Amlodipine CPG (clopidogrel) Bisoprolol Metformin	Amlodipine – simvastatin Amlodipine - metformin Amlodipine – bisoprolol	Serius / Mayor Monitor closely/ Moderat	Farmakodinam ik antagonis Farmakodinam ik sinergis	Amlodipine – simvastatin Amlodipine – bisoprolol	Mayor Moderat	

						Bisoprolol – candesartan		Farmakodinam ik sinergis			
49	Ny. SW	P	41 Th	CHF	Miniaspi (aspirin) Simvastatin Bisoprolol Nitrokaf retard (nitroglicer in) Alprazolam	Aspirin – bisoprolol	<i>Monitor Closely / Moderat</i>	Farmakodinam ik antagonis	Alprazolam – nitroglicer in Alprazolam – bisoprolol Aspirin – nitroglicer in Aspirin – bisoprolol	Moderat Moderat Minor Minor	
50	Tn. S	L	73 Th	CHF CAD DM	Metformin Lansoprazol e ISDN Ramipril Miniaspi Spironolacto ne	Aspirin – ramipril Ramipril – spironolacto ne Ramipril – metformin Aspirin – spironolasto ne	Serius / mayor <i>Monitor Closely / Moderat</i>	Farmakodinam ik antagonis Farmakodinam ik sinergis Tidak diketahui Tidak diketahui	Ramipril – spironolacto ne Aspirin – ramipril ISDN – ramipril Spironolacto ne – metformin Ramiril – metformin	Mayor Moderat Moderat Moderat Moderat Minor	

									Aspirin – spironolactone Aspirin – lansoprazole	Minor	
51	Tn. B	L	59 Th	CHD Dislipidemia	CPG (clopidogrel) Concor (bisoprolol) Atorvastatin lansoprazole	Lansoprazole – clopidogrel	<i>Monitor Closely / Moderat</i>		Lansoprazole – clopidogrel Lansoprazole – atorvastatin Atorvastatin – clopidogrel	Moderat Moderat Moderat	
52	Ny. K	P	62 Th	CHF	Uperio (sacubitril /valsartan) Simvastatin Miniaspi (aspirin) Bisoprolol Alprazolam Ciprofloxacin	Aspirin – bisoprolol Aspirin – sacubitril/valsartan Bisoprolol – sacubitril/valsartan Simvastatin – sacubitril/valsartan	<i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i>	Farmakodinamik antagonis Farmakodinamik antagonis Farmakodinamik sinergis	Ciprofloxacin – aspirin Alprazolam – bisoprolol Ciprofloxacin – simvastatin Alprazolam – valsartan Aspirin – valsartan Bisoprolol – valsartan	Moderat Moderat Moderat Moderat Moderat Moderat	

						Aspirin – ciprofloxac in	Minor		Simvastatin – sacubitril	Minor	
						Sacubitril/va lsartan – simvastatin Ciprofloxac in – alprazolam	Minor		Aspirin – bisoprolol		
53	Ny. TS	P	45 Th	CHF IHD Hipertensi	Alprazolam Irbesartan Bisoprolol Nospirinal (aspirin) Furosemide Simvastatin Amlodipine	Amlodipine – simvastatin	Serius / mayor		Amlodipine – simvastatin	Mayor	
						Bisoprolol – amlodipine	<i>Monitor Closely / Moderat</i>	Farmakodinam ik sinergis	Furosemide – alprazolam	Moderat	
						Bisoprolol – irbesartan	<i>Monitor Closely / Moderat</i>	Farmakodinam ik sinergis	Alprazolam – amlodipine	Moderat	
						Aspirin – bisoprolol	<i>Monitor Closely / Moderat</i>	Farmakodinam ik antagonis	Aspirin – amlodipine	Moderat	
						Aspirin – irbesartan	<i>Monitor Closely / Moderat</i>	Farmakodinam ik antagonis	Furosemide – bisoprolol	Moderat	
						Irbesartan – furosemide	<i>Monitor Closely / Moderat</i>		Alprazolam – bisoprolol	Moderat	
						Bisoprolol – furosemide			Amlodipine – bisoprolol	Moderat	

						Aspirin – furosemide	Minor	Farmakodinamik antagonis	Alprazolam – irbesartan Aspirin – irbesartan Furosemide – aspirin Aspirin – bisoprolol	Moderat Minor Minor	
54	Ny. SH	P	70 Th	CHF	Miniaspi (aspirin) Simvastatin Candesartan Bisoprolol allopurinol	Bisoprolol – candesartan Aspirin – bisoprolol Aspirin – candesartan	<i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i>	Farmakodinamik sinergis Farmakodinamik antagonis Farmakodinamik antagonis	Aspirin – candesartan Aspirin – bisoprolol	Moderat Minor	
55	Ny. S	P	53 Th	CHF	Beraprost Simvastatin Bisoprolol Nospirinal Alprazolam	Aspirin – bisoprolol	<i>Monitor Closely / Moderat</i>	Farmakodinamik antagonis	Alprazolam – bisoprolol Aspirin – bisoprolol	Moderat Minor	
56	Ny. M	P	60 Th	CHF CHD Vertigo	Alprazolam Simvastatin Candesartan Nitrokaf retard (nitroglicerine)	Aspirin – candesartan	<i>Monitor Closely / Moderat</i>	Farmakodinamik antagonis	Alprazolam – nitroglicerine Simvastatin – lansoprazole	Moderat Moderat Moderat Moderat	

					Nospirinal Lansoprazole				Alprazolam – candesartan Aspirin – candesartan Aspirin – nitroglycerin Aspirin – lansoprazole	Minor Minor	
57	Ny. D	P	69 Th	CHF IHD	Miniaspi (aspirin) Simvastatin Candesartan Bisoprolol Omeprazole	Bisoprolol – candesartan Aspirin – bisoprolol Aspirin – candesartan	<i>Monitor Closely / Moderat Monitor Closely / Moderat</i>	Farmakodinam ik sinergis Farmakodinam ik antagonis Farakodinamik antagonis	Aspirin – candesartan Omeprazole – simvastatin Aspirin – omeprazole Aspirin – bisoprolol	Moderat Moderat Minor Minor	
58	Ny. NS	P	42 Th	CHF IHD	Beraprost Alprazolam Candesartan Mecobalamin Bisoprolol Nitrokaf retard	Bisoprolol – candesartan	<i>Monitor Closely / Moderat</i>	Farmakodinam ik sinergis	Alprazolam – nitroglycerin Alprazolam – bisoprolol Alprazolam – candesartan	Moderat Moderat Moderat	

					(nitoglicerin)						
59	Ny. S	P	93 Th	CHF Hipertensi	Clopidogrel Lansoprazole Candesartan Amiodarone Bisoprolol	Bisoprolol – candesartan Amiodarone – bisoprolol Lansoprazole – clopidogrel	<i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i>	Farmakodinamik sinergis Farmakodinamik sinergis	Amiodarone – bisoprolol Amiodarone – clopidogrel Lansoprazole – clopidogrel	Moderat Moderat Moderat	
60	Ny. H	P	52 Th	CHF IHD DM	Metformin Furosemide Spironolactone Candesartan Allopurinol mecobalamin	Spironolactone – furosemide Candesartan – spironolactone Candesartan – furosemide Metformin – furosemide Metformin – mecobalamin	<i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i> Minor Minor		Spironolactone – candesartan Furosemide – metformin Spironolactone – metformin	Mayor Moderat Moderat	

61	Ny. S	P	65 Th	CHF IHD	Spironolactone Furosemide Simvastatin Bisoprolol Miniaspi (aspirin) Candesartan Lansoprazole	Bisoprolol – candesartan Aspirin – bisoprolol Aspirin – candesartan Aspirin – spironolactone Aspirin – furosemide	<i>Monitor Closely /</i> Moderat <i>Monitor Closely /</i> Moderat <i>Monitor Closely /</i> Moderat Minor	Farmakodinamik sinergis Farmakodinamik antagonis Farmakodinamik antagonis Tidak diketahui Farmakodinamik antagonis	Spironolactone – candesartan Furosemide – bisoprolol Spironolactone – bisoprolol Furosemide – lansoprazole Simvastatin – lansoprazole Aspirin – candesartan Furosemide – aspirin Aspirin – spironolactone Aspirin – bisoprolol Aspirin – lansoprazole	Mayor Moderat Moderat Moderat Moderat Moderat Minor Minor Minor Minor	
----	-------	---	----------	------------	---	--	--	--	--	--	--

62	Tn. BS	L	62 Th	NSTEMI	ISDN Furosemide Irbesartan Nospirinal (aspirin) Simvastatin Bisoprolol Alprazolam	Bisoprolol – irbesartan Aspirin – bisoprolol Aspirin – irbesartan Irbesrtan – furosemide Aspirin – furosemide	<i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i> <i>Monitor closely/ Moderat</i> <i>Minor</i>	Farmakodinam ik sinergis Farmakodinam ik antagonis Farmakodinam ik antagonis Farmakodinam ik antagonis	Furosemide – alprazolam Alprazolam – ISDN Furosemide – bisoprolol Alprazolam – bisoprolol Alprazolam – irbesartan Aspirin – irbesartan Furosemide – aspirin Aspirin – bisoprolol	Moderat Moderat Moderat Moderat Moderat Minor Minor	
63	Tn. SN	L	53 Th	CKD	Simvatstain Furosemide Amlodipine Candesartan Bisoprolol	Amlodipine – simvastatin Bisoprolol – amlodipine – bisoprolol – candesartan Bisoprolol – furosemide Candesartan – furosemide	<i>Serius / mayor</i> <i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i> <i>Monitor Closely</i>	Farmakodinam ik sinergis Farmakodinam ik sinergis	Amlodipine – simvastatin Furosemide – bisoprolol Bisoprolol – amlodipine	Mayor Moderat Moderat	

64	Ny. S	P	77 Th	CHD IHD	Miniaspi (aspirin) Alprazolam Simvastatin Bisoprolol Candesartan Furosemide	Bisoprolol – candesartan Aspirin – bisoprolol Aspirin – candesartan Candesartan – furosemide Bisoprolol – furosemide Aspirin – furosemide	<i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i> <i>Monitor closely/ moderat</i> Minor	Farmakodinam ik sinergis Farmakodinam ik antagonis Farmakodinam ik antagonis Farmakodinam ik antagonis	Furosemide – alprazolam Furosemide – bisoprolol Alprazolam – bisoprolol Alprazolam – candesartan Aspirin – candesartan Furosemide – aspirin Aspirin – bisoprolol	Moderat Moderat Moderat Moderat Moderat Minor Minor	
65	Ny. S	P	60 Th	CKD	Bisoprolol Fenofibrate Lansoprazol e Spironolacto ne Nitrokaf retard (nitroglicer in) Miniaspi (aspirin)	Aspirin – bisoprolol Aspirin – spironolacto ne Bisoprolol – spironolacto ne	<i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i>	Farmakodinam ik antagonis Tidak diketahui	Spironolacto ne – bisoprolol Lansoprazol e – fenofibrate Aspirin – nitroglicer in Aspirin – spironolacto ne	Moderat Moderat Minor Minor Minor	

									Aspirin – bisoprolol Aspirin – lansoprazole	Minor	
66	Ny. J	P	68 Th	CHF IHD	Uperio (sacubitril/valsartan) Beraprost Simvastatin Nospirinal (aspirin) Lansoprazole Mecobalamin	Aspirin – sacubitril/valsartan Simvastatin – sacubitril/valsartan Lansoprazole – mecobalamin Aspirin – mecobalamin	<i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i> Minor	Farmakodinamik antagonis	Simvastatin – lansoprazole Aspirin – sacubitril/valsartan Simvastatin – sacubitril/valsartan Aspirin – lansoprazole Lansoprazole – mecobalamin	Moderat Moderat Moderat Minor Minor	
67	Tn. AS	L	66 Th	CHF IHD	Candesartan Furosemide Miniaspi Nospirinal (aspirin) Simvastatin Bisoprolol	Bisoprolol – candesartan Aspirin – bisoprolol Aspirin – candesartan	<i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i>	Farmakodinamik sinergis Farmakodinamik antagonis Farmakodinamik antagonis	Furosemide – bisoprolol Aspirin – candesartan Furosemide – aspirin	Moderat Moderat Minor	

						Candesartan – furosemide Bisoprolol – furosemide	<i>Monitor Closely / Moderat</i>		Aspirin – bisoprolol	Minor	
						Aspirin – furosemide	Minor	Farmakodinamik antagonis			
68	Ny. S	P	67 Th	CHF HHD	Miniaspi (aspirin) Bisoprolol Candesartan Atorvastatin Lansoprazole	Bisoprolol – candesartan Aspirin – bisoprolol Aspirin – candesartan	<i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i>	Farmakodinamik sinergis Farmakodinamik antagonis Farmakodinamik antagonis	Lansoprazole – atorvastatin Aspirin – candesartan Aspirin – bisoprolol Aspirin – lansoprazole	Moderat Moderat Minor Minor	
69	Tn. JS	L	58 Th	CAD Dislipidemia	CPG (clopidogrel) Lansoprazole Aspilet (aspirin) Simvastatin	Aspirin – clopidogrel Lansoprazole – clopidogrel	<i>Monitor Closely / Moderat</i>	Farmakodinamik sinergis	Simvastatin – lansoprazole Aspirin – clopidogrel Lansoprazole – clopidogrel Aspirin – lansoprazole	Moderat Moderat Moderat Minor	

70	Ny. T	P	69 Th	CHF IHD	Candesartan Simvastatin Bisoprolol Nospirinal (aspirin) Nitrokaf retard (nitroglicerine) Lansoprazole	Bisoprolol – candesartan Aspirin – bisoprolol Aspirin – candesartan	<i>Monitor Closely / Moderat Monitor Closely / Moderat</i>	Farmakodinamik sinergis Farmakodinamik antagonis Farmakodinamik antagonis	Simvastatin – lansoprazole Aspirin – candesartan Aspirin – nitroglicerine Aspirin – bisoprolol Aspirin – lansoprazole	Moderat Moderat Minor Minor Minor	
71	Tn. S	L	68 Th	CAD Dislipidemia	Candesartan Amlodipine Simvastatin Miniaspirin (aspirin) Allopurinol	Amlodipine – simvastatin Aspirin – candesartan	Serius / mayor <i>Monitor Closely / Moderat</i>	Farmakodinamik antagonis	Amlodipine – simvastatin Aspirin – amlodipine Aspirin – candesartan	Mayor Moderat Moderat	
72	Ny. P	P	64 Th	CHF IHD DM	Nospirinal (aspirin) Simvastatin Bisoprolol Candesartan Nitrokaf retard	Bisoprolol – candesartan Aspirin – bisoprolol Aspirin – candesartan	<i>Monitor Closely / Moderat Monitor Closely / Moderat</i>	Farmakodinamik sinergis Farmakodinamik antagonis Farmakodinamik antagonis	Aspirin – candesartan Aspirin – nitroglicerine Aspirin – bisoprolol	Moderat Minor Minor	

					(nitroglicerine) Metformin						
73	Ny. R	P	62 Th	CHF IHD	Uperio (sacubitril/valsartan) Simvastatin Bisoprolol Lansoprazole Nospirinal (aspirin)	Aspirin – bisoprolol Aspirin – sacubitril/valsartan Bisoprolol – sacubitril/valsartan Simvastatin – sacubitril/valsartan	<i>Monitor Closely /</i> Moderat <i>Monitor Closely /</i> Moderat <i>Monitor Closely /</i> Moderat	Farmakodinamik antagonis Farmakodinamik antagonis Farmakodinamik sinergis	Simvastatin – lansoprazole Aspirin – sacubitril/valsartan Bisoprolol – sacubitril/valsartan Simvastatin – sacubitril/valsartan Aspirin – bisoprolol Aspirin – lansoprazole	Moderat Moderat Moderat Moderat Minor Minor	
74	Ny. J	P	54 Th	CHF IHD	Alprazolam Bisoprolol Nospirinal (aspirin) Simvastatin Candesartan	Bisoprolol – candesartan Aspirin – bisoprolol Aspirin – candesartan	<i>Monitor Closely /</i> Moderat Monitor closely/ Moderat	Farmakodinamik sinergis Farmakodinamik antagonis Farmakodinamik antagonis	Alprazolam – bisoprolol Alprazolam – candesartan Aspirin – candesartan	Moderat Moderat Moderat	

									Aspirin – bisoprolol	Minor	
75	Tn. K	L	64 Th	CHF IHD	Uperio (sacubitril/valsartan) Bisoprolol Simvastatin ISDN Nospirinal (aspirin) Lansoprazole Mecobalamine	Aspirin – bisoprolol Aspirin – sacubitril/valsartan Bisoprolol – sacubitril/valsartan Simvastatin – sacubitril/valsartan Lansoprazole – mecobalamine Aspirin – mecobalamine	<i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i> Minor Minor	Farmakodinamik antagonis Farmakodinamik antagonis Farmakodinamik sinergis	Simvastatin – lansoprazole Aspirin – sacubitril/valsartan Bisoprolol – sacubitril/valsartan Simvastatin – sacubitril/valsartan Aspirin – bisoprolol Aspirin – lansoprazole Lansoprazole – mecobalamine	Moderat Moderat Moderat Moderat Minor Minor Minor	
76	Ny. RD	P	33 Th	CHF	Simvastatin Bisoprolol	Aspirin – bisoprolol	<i>Monitor Closely / Moderat</i>	Farmakodinamik antagonis	Simvastatin – lansoprazole	Moderat	

					Lansoprazole Nospirinal (aspirin)				Aspirin – bisoprolol Aspirin – lansoprazole	Minor Minor	
77	Ny. R	P	71 Th	IHD CHF Hipertensi	Alprazolam Atorvastatin Bisoprolol Candesartan Miniaspi (aspirin) Furosemide Spironolactone	Bisoprolol – candesartan Aspirin – bisoprolol Aspirin – spironolactone Aspirin – candesartan Spironolactone – furosemide Aspirin – furosemide	<i>Monitor Closely /</i> Moderat <i>Monitor Closely /</i> Moderat <i>Monitor Closely /</i> Moderat <i>Monitor Closely /</i> Moderat Minor	Farmakodinamik sinergis Farmakodinamik antagonis Tidak diketahui Farmakodinamik antagonis Farmakodinamik antagonis	Spironolactone – candesartan Furosemide – alprazolam Alprazolam – spironolactone Furosemide – bisoprolol Alprazolam – bisoprolol Spironolactone – bisoprolol Alprazolam – candesartan Aspirin – candesartan	Mayor Moderat Moderat Moderat Moderat Moderat Moderat Moderat Minor Minor	

									Furosemide – aspirin Aspirin – spironolactone Aspirin – bisoprolol	Minor	
78	Tn. SS	L	72 Th	CHF	Nospirinal (aspirin) Simvastatin Bisoprolol Lansoprazole	Aspirin – bisoprolol	<i>Monitor Closely / Moderat</i>	Farmakodinamik antagonis	Simvastatin – lansoprazole Aspirin – bisoprolol Aspirin – lansoprazole	Moderat Minor Minor	
79	Ny. M	P	56 Th	CHF Hipertensi	Spironolactone Digoxin Bisoprolol Furosemide	Digoxin – bisoprolol Bisoprolol – digoxin Furosemide – digoxin Spironolactone – digoxin Bisoprolol – spironolactone	Serius / mayor <i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i>	 Farmakodinamik sinergis Farmakodinamik sinergis	Furosemide – digoxin Furosemide – bisoprolol Digoxin – bisoprolol Spironolactone – bisoprolol Digoxin – spironolactone	Moderat Moderat Moderat Moderat Minor	

						Spironolactone – furosemide Bisoprolol – furosemide	<i>Monitor Closely / Moderat</i>				
80	Ny. S	P	74 Th	CHF Hipertensi	Irbesartan Bisoprolol Allopurinol Furosemide Lansoprazole Nitrogliserin retard (nitroglicerine) Nospirinal (aspirin)	Bisoprolol – irbesartan Aspirin – bisoprolol Aspirin – irbesartan Irbesartan – furosemide Bisoprolol – furosemide Aspirin – furosemide	<i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i> <i>Minor</i>	Farmakodinamik sinergis Farmakodinamik antagonis Farmakodinamik antagonis	Furosemide – bisoprolol Furosemide – lansoprazole Aspirin – irbesartan Furosemide – aspirin Aspirin – nitroglicerine Aspirin – bisoprolol Aspirin – lansoprazole	Moderat Moderat Moderat Minor Minor Minor Minor	
81	Tn. SK	L	34 Th	CHF	Lansoprazole Ondancetron Miniaspirin (aspirin) Simvastatin Bisoprolol	Aspirin – bisoprolol Bisoprolol – furosemide Aspirin – furosemide	<i>Monitor Closely / Moderat</i> <i>Minor</i>	Farmakodinamik antagonis Farmakodinamik antagonis	Furosemide – bisoprolol Furosemide – lansoprazole	Moderat Moderat Moderat	

					Furosemide Ranitidine				Simvastatin – lansoprazole Furosemide – aspirin Aspirin – bisoprolol Aspirin – lansoprazole	Minor Minor Minor	
82	Tn. S	L	79 Th	CHF Hipertensi	Irbesartan Amlodipine Candesartan Bisoprolol Simvastatin Nospirinal (aspirin)	Amlodipine – simvastatin Bisoprolol – amlodipine Bisoprolol – candesartan Bisoprolol – irbesartan Aspirin – bisoprolol Aspirin – candesartan Aspirin – irbesartan	Serius / mayor <i>Monitor</i> <i>Closely</i> / Moderat <i>Monitor</i> <i>Closely</i> / Moderat <i>Monitor</i> <i>Closely</i> / Moderat <i>Monitor</i> <i>Closely</i> / Moderat	Farmakodinam ik sinergis Farmakodinam ik sinergis Farmakodinam ik sinergis Farmakodinam ik antagonis Farmakodinam ik antagonis Farmakodinam ik antagonis	Amlodipine – simvastatin Aspirin – amlodipine Amlodipine – bisoprolol Aspirin – irbesartan Aspirin – candesartan Aspirin – bisoprolol	Mayor Moderat Moderat Moderat Moderat Minor	

83	Ny. M	P	59 Th	CHF Hipertensi	Diovan (valsartan) Amlodipine Bisoprolol Alprazolam Miniaspi (aspirin) Nitrokaf retard (nitroglicerine)	Bisoprolol – valsartan Aspirin – bisoprolol Bisoprolol – amlodipine Aspirin – valsartan	<i>Monitor</i> <i>Closely</i> / Moderat <i>Monitor</i> <i>Closely</i> / Moderat <i>Monitor</i> <i>Closely</i> / Moderat	Farmakodinam ik sinergis Farmakodinam ik antagonis Farmakodinam ik sinergis Farmakodinam ik antagonis	Alprazolam – nitroglicerine Alprazolam – amlodipine Apirin – amlodipine Nitroglicerine – amlodipine Alprazolam – bisoprolol Amlodipine – bisoprolol Alprazolam – valsartan Aspirin – valsartan Bisoprolol – valsartan Aspirin – nitroglicerine Aspirin – bisoprolol	Moderat Moderat Moderat Moderat Moderat Moderat Moderat Moderat Moderat Minor Minor	
----	----------	---	----------	-------------------	--	--	---	--	---	---	--

84	Tn. S	L	79 Th	CHF Hipokalemi a Bradikardi	Kompolac Furosemide Beraprost Miniaspi (aspirin) Candesartan Bisoprolol	Bisoprolol – candesartan Aspirin – bisoprolol Aspirin – candesartan Candesartan – furosemide Bisoprolol – furosemide Aspirin – furosemide	<i>Monitor Closely / Moderat Monitor Closely / Moderat Monitor Closely / Moderat Monitor Closely Moderat Minor</i>	Farmakodinam ik sinergis Farmakodinam ik antagonis Farmakodinam ik antagonis Farmakodinam ik antagonis	Furosemide – bisoprolol Aspirin – candesartan Furosemide – aspirin Aspirin – bisoprolol	Moderat Moderat Minor Minor	
85	Tn. MA M	L	67 Th	CHF	Lansoprazol e Ondancetron Miniaspi (aspirin) Simvastatin Bisoprolol Furosemide Ranitidine	Aspirin – bisoprolol Bisoprolol – furosemide Aspirin – furosemide	<i>Monitor Closely / Moderat Minor</i>	Farmakodinam ik antagonis Farmakodinam ik antagonis	Furosemide – bisoprolol Furosemide – lansoprazole Simvastatin – lansoprazole Furosemide – aspirin Aspirin – bisoprolol	Moderat Moderat Moderat Minor Minor Minor	

									Aspirin – lansoprazole		
86	Tn. AH	L	67 Th	CHF	Nospirinal (aspirin) Simvastatin Bisoprolol Lansoprazole	Aspirin – bisoprolol	<i>Monitor Closely / Moderat</i>	Farmakodinamik antagonis	Simvastatin – lansoprazole Aspirin – bisoprolol Aspirin – lansoprazole	Moderat Minor Minor	
87	Ny. S	P	42 Th	CHF IHD	Lansoprazole Nospirinal (aspirin) Bisoprolol Simvastatin Nitrokaf retard (nitroglicerine)	Aspirin – bisoprolol	<i>Monitor Closely / Moderat</i>	Farmakodinamik antagonis	Simvastatin – lansoprazole Aspirin – bisoprolol Aspirin – lansoprazole	Moderat Minor Minor	
88	Ny. S	P	76 Th	CHF IHD	Alprazolam Nospirinal (aspirin) Lansoprazole Simvastatin Bisoprolol Candesartan	Bisoprolol – candesartan Aspirin – bisoprolol Aspirin – candesartan	<i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i>	Farmakodinamik sinergis Farmakodinamik antagonis Farmakodinamik antagonis	Alprazolam – bisoprolol Simvastatin – lansoprazole Alprazolam – candesartan	Moderat Moderat Moderat Moderat	

									Aspirin – candesartan	Minor	
									Aspirin – bisoprolol Aspirin – lansoprazole	Minor	
89	Tn. WE	L	63 Th	CAD CHF	Miniaspi (aspirin) Alprazolam CPG (clopidogrel) Lansoprazol e Atorvastatin Nitrokaf retard (nitroglicerine) Bisoprolol	Aspirin – bisoprolol Aspirin – clopidogrel Lansoprazol e – clopidogrel	Monitor closely/ Moderat <i>Monitor</i> <i>Closely</i> / Moderat	Farmakodinam ik antagonis Farmakodinam ik sinergis	Alprazolam – nitroglicerine Alprazolam – bisoprolol Lansoprazol e – atorvastatin Aspirin – clopidogrel Lansoprazol e – clopidogrel Atorvastatin – clopidogrel Aspirin – nitroglicerine Aspirin – bisoprolol	Moderat Moderat Moderat Moderat Moderat Minor Minor Minor	

									Aspirin – lansoprazole		
90	Tn. TSI	L	75 Th	CHF IHD DM	Furosemide Miniaspi (aspirin) Simvastatin Bisoprolol Candesartan Irbesartan Allopurinol Metformin	Bisoprolol – candesartan Bisoprolol – irbesartan Aspirin – bisoprolol Aspirin – candesartan Aspirin – irbesartan Candesartan – furosemide Irbesartan – furosemide Bisoprolol – furosemide Aspirin – furosemide Metformin – furosemide	<i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i> Minor Minor	Farmakodinam ik sinergis Farmakodinam ik sinergis Farmakodinam ik antagonis Farmakodinam ik antagonis Farmakodinam ik antagonis Farmakodinam ik antagonis	Furosemide – bisoprolol Furosemide – metformin Aspirin – irbesartan Aspirin – candesartan Furosemide – aspirin Aspirin – bisoprolol	Moderat Moderat Moderat Moderat Minor Minor	
91	Ny. P	P	64 Th	CHF IHD Hipertensi	Amlodipine Miniaspi (aspirin) Simvastatin	Amlodipine – simvastatin	Serius / mayor		Amlodipine – simvastatin	Mayor Moderat	

					Allopurinol Candesartan	Aspirin – candesartan	<i>Monitor Closely / Moderat</i>	Farmakodinam ik antagonis	Aspirin – amlodipine Aspirin – candesartan	Moderat	
92	Ny. P	P	72 Th	CHF Dislipidemi a	ISDN Miniaspi (aspirin) Candesartan Alprazolam Lansoprazol e Furosemide	Aspirin – candesartan Candesartan – furosemide Aspirin – furosemide	<i>Monitor Closely / Moderat Monitor Closely</i> Minor	Farmakodinam ik antagonis Farmakodinam ik antagonis	Furosemide – alprazolam Alprazolam – ISDN Furosemide – lansoprazole Alprazolam – candesartan Aspirin – candesartan Furosemide – aspirin Aspirin – lansoprazole	Moderat Moderat Moderat Moderat Moderat Minor Minor	
93	Ny. M	P	68 Th	CHF IHD	Nospirinal (aspirin) Mecobalami n Simvastatin Alprazolam	Bisoprolol – candesartan Aspirin – bisoprolol Aspirin – candesartan	<i>Monitor Closely / Moderat Monitor Closely / Moderat</i>	Farmakodinam ik sinergis Farmakodinam ik antagonis Farmakodinam ik antagonis	Alprazolam – bisoprolol Alprazolam – candesartan	Moderat Moderat Moderat	

					Bisoprolol Candesartan				Aspirin – candesartan	Minor	
									Aspirin – bisoprolol		
94	Ny. S	P	83 Th	CHF Pneumonia PPOK	Mecobalami n Simvastatin Alprazolam Bisoprolol Candesartan Nospirinal (aspirin)	Bisoprolol – candesartan Aspirin – bisoprolol Aspirin – candesartan	<i>Monitor Closely / Moderat Monitor Closely / Moderat</i>	Faramkodinam ik sinergis Farmakodinam ik antagonis Farmakodinam ik antagonis	Alprazolam – bisoprolol Alprazolam – candesartan Aspirin – candesartan Aspirin – bisoprolol	Moderat Moderat Moderat Minor	
95	Ny. N	P	64 Th	CHF	Furosemide Spironolacto ne Digoxin Atorvastatin CPG (clopidogrel) Nitrokaf retard (nitroglicerine)	Furosemide – digoxin Atorvastatin- digoxin Spironolacto ne – digoxin Spironolacto ne – furosemide	<i>Monitor Closely / Moderat Monitor Closely / Moderat</i>	Farmakodinam ik sinergis	Furosemide – digoxin Digoxin – atorvastatin Atorvastatin – clopidogrel Digoxin – spironolacto ne	Moderat ae Moderat Moderat Minor	

96	Ny. S	P	46 Th	CHF IHD Hipertensi	CPG (clopidogrel) Simvastatin Bisoprolol Alprazolam Candesartan Amlodipine	Amlodipine – simvastatin Bisoprolol – amlodipine Bisoprolol – candesartan	Serius / mayor <i>Monitor Closely / Moderat</i>	Farmakodinamik sinergis Farmakodinamik sinergis	Amlodipine – simvastatin Alprazolam – amlodipine Alprazolam – bisoprolol Amlodipine – bisoprolol Alprazolam – candesartan	Mayor Moderat Moderat Moderat Moderat	
97	Ny. SB	P	60 Th	CHF DM	Simvastatin Metformin Allopurinol Miniaspi (aspirin) Bisoprolol Candesartan	Bisoprolol – candesartan Aspirin – bisoprolol Aspirin – candesartan	<i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i>	Farmakodinamik sinergis Farmakodinamik antagonis Farmakodinamik antagonis	Aspirin – candesartan Aspirin – bisoprolol	Moderat Minor	
98	Ny. S	P	60 Th	CHF	Omeprazole Bisoprolol Simvastatin Spironolactone Candesartan	Bisoprolol – candesartan Candesartan – spironolactone	<i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i>	Farmakodinamik sinergis	Spironolactone – candesartan Spironolactone – bisoprolol	Mayor Moderat Moderat	

					Nitrokaf retard (nitroglicerine)	Bisoprolol – spironolactone			Omeprazole – simvastatin Nitroglicerine – omeprazole	Minor	
99	Ny. W	P	72 Th	CHF Nstemi	Fenofibrat Amlodipine Bisoprolol Candesartan CPG (clopidogrel)	Bisoprolol – candesartan Bisoprolol – amlodipine	<i>Monitor Closely / Moderat</i>	Farmakodinamik sinergis Farmakodinamik sinergis	Amlodipine – bisoprolol Clopidogrel – fenofibrate	Moderat Moderat	
100	Tn. INH	L	57 Th	CKD Anemia	Irbesartan Amlodipine Bisoprolol Candesartan Nospirinal (aspirin) Simvastatin	Amlodipine – simvastatin Bisoprolol – amlodipine Bisoprolol – candesartan Bisoprolol – irbesartan Aspirin – bisoprolol Aspirin – candesartan Aspirin – irbesartan	Serius / mayor <i>Monitor Closely / Moderat Monitor Closely / Moderat Monitor Closely Moderat Monitor Closely / Moderat</i>	Farmakodinamik sinergis Farmakodinamik sinergis Farmakodinamik sinergis Farmakodinamik antagonis Farmakodinamik antagonis Farmakodinamik antagonis	Amlodipine – simvastatin Aspirin – amlodipine Amlodipine – bisoprolol Aspirin – irbesartan Aspirin – candesartan Aspirin – bisoprolol	Mayor Moderat Moderat Moderat Moderat Minor	

101	Tn.K HK	L	66 Th	CHF DM	Metformin Simvastatin Bisoprolol CPG (clopidogrel) ISDN Digoxin	Digoxin – bisoprolol Bisoprolol – digoxin Simvastatin – digoxin Digoxin – metformin	Serius / mayor <i>Monitor</i> <i>Closely</i> / Moderat <i>Monitor</i> <i>Closely</i> / Moderat	Farmakodinam ik sinergis	Digoxin – bisoprolol Digoxin – metformin	Moderat Moderat	
102	Tn. S	L	58 Th	CHF IHD HHD	Uperio (sacubitril/va lsartan) Simvastatin Miniaspi (aspirin) Candesartan Bisoprolol Furosemide Lansoprazol e	Bisoprolol – candesartan Aspirin – bisoprolol Bisoprolol – sacubitril/val sartan Aspirin – candesartan Aspirin – sacubitril/val sartan Candesartan – furosemide Bisoprolol – furosemide Simvastatin –	<i>Monitor</i> <i>Closely</i> / Moderat <i>Monitor</i> <i>Closely</i> / Moderat <i>Monitor</i> <i>Closely</i> / Moderat <i>Monitor</i> <i>Closely</i> / Moderat <i>Monitor</i> <i>Closely</i> / Moderat	Farmakodinam ik sinergis Farmakodinam ik antagonis Farmakodinam ik sinergis Farmakodinam ik antagonis Farmakodinam ik antagonis	Furosemide – bisoprolol Furosemide – lansoprazole Simvastatin – lansoprazole Aspirin – sacubitril/va lsartan Bisoprolol – sacubitril/va lsartan Aspirin – candesartan Simvastatin –	Moderat Moderat Moderat Moderat Moderat Moderat Moderat	

						sacubitril/valsartan Aspirin – furosemide	Minor	Farmakodinamik antagonis	sacubitril/valsartan Furosemide – aspirin Aspirin – bisoprolol Aspirin – lansoprazole	Minor Minor Minor	
103	Ny. S	P	79 Th	CHF Hipertensi	Amlodipine Lansoprazole Candesartan Ceftriaxone Simvastatin	Amlodipine – simvastatin	Serius / mayor		Amlodipine – simvastatin Ceftriaxone – lansoprazole Simvastatin – lansoprazole	Mayor Moderat Moderat	
104	Tn. S	L	62 Th	CAD Dislipidemia	Amlodipine Simvastatin ISDN CPG (clopidogrel)	Amlodipine – simvastatin	Serius / mayor		Amlodipine – simvastatin	Mayor	
105	Ny. S	P	61 Th	DM CHF	Inj. Humalog (insulin lispro)	Fenofibrate – atorvastatin	Serius / mayor	Farmakodinamik sinergis	Gemfibrozil – atorvastatin	Mayor Mayor	

					Inj. Sansulin (insulin glargine) Lansoprazol e Allopurinol Fenofibrate Atorvastatin Candesartan NR Gemfibrozil	Gemfibrozil – atorvastatin Fenofibrate – insulin lispro Gemfibrozil – insulin lispro Fenofibrate – insulin glargine Gemfibrozil – insulin glargine Candesartan – insulin glargine Candesartan – insulin lispro	Serius / mayor <i>Monitor</i> <i>Closely</i> / Moderat <i>Monitor</i> <i>Closely</i> / Moderat <i>Monitor</i> <i>Closely</i> / Moderat <i>Monitor</i> <i>Closely</i> / Moderat <i>Monitor</i> <i>Closely</i> / Moderat	Farmakodinam ik sinergis	Atorvastatin – fenofibrate Lansoprazol e – atorvastatin Lansoprazol e – fenofibrate Gemfibrozil – insulin lispro Fenofibrate – insulin lispro Candesartan – insulin lispro Gemfibrozil – insulin glargine Fenofibrate – insulin glargine Candesartan – insulin glargine	Moderat Moderat Moderat Moderat Moderat Moderat Moderat Moderat	
--	--	--	--	--	--	--	--	-----------------------------	--	--	--

106	Tn. ES	L	70 Th	CHF IHD Hipertensi	Simvastatin Candesartan CPG (clopidogrel) Bisoprolol Amlodipine	Amlodipine – simvastatin Bisoprolol – amlodipine Bisoprolol – candesartan	Serius / mayor <i>Monitor Closely / Moderat</i>	Farmakodinamik sinergis Farmakodinamik sinergis	Amlodipine – simvastatin Amlodipine – bisoprolol	Mayor Moderat	
107	Tn. AS	L	61 Th	CHF IHD Hipertensi	Nospirinal (aspirin) Simvastatin Bisoprolol Amlodipine Irbesartan	Amlodipine – simvastatin Bisoprolol – amlodipine Bisoprolol – irbesartan Aspirin – bisoprolol Aspirin – irbesartan	Serius / mayor Moderat Moderat Moderat Moderat	Farmakodinamik sinergis Farmakodinamik sinergis Farmakodinamik antagonis Farmakodinamik antagonis	Amlodipine – simvastatin Aspirin – amlodipine Amlodipine – bisoprolol Aspirin – irbesartan Aspirin – bisoprolol	Mayor Moderat Moderat Moderat Minor	
108	Tn. M	L	61 Th	CHF CAD	Aspilet (aspirin) CPG (clopidogrel) Atorvastatin ISDN Bisoprolol	Aspirin – bisoprolol Aspirin – clopidogrel	<i>Monitor Closely / Moderat</i>	Farmakodinamik antagonis Farmakodinamik sinergis	Aspirin – clopidogrel Atorvastatin – clopidogrel	Moderat Moderat Minor	

					Allopurinol				Aspirin – bisoprolol		
109	Tn. S	L	72 Th	CHF IHD	Uperio (sacubitril/valsartan) Simvastatin CPG (clopidogrel) Trimetropim Beraprost	Sacubitril/valsartan – trimethoprim Simvastatin – sacubitril/valsartan	Monitor Closely / Moderat Monitor Closely / Moderat		Trimethoprim – sacubitril/valsartan Simvastatin – sacubitril/valsartan	Mayor Moderat	
110	Tn. W	L	62 Th	CHF	Bisoprolol ISDN Spironolactone Simvastatin Furosemide	Bisoprolol – spironolactone Spironolactone – furosemide Bisoprolol – furosemide	Monitor Closely / Moderat Monitor Closely / Moderat		Furosemide – bisoprolol Spironolactone – bisoprolol		
111	Ny. S	P	66 Th	CHF IHD	Ciprofloxacin Bisoprolol Candesartan Lansoprazole Miniaspi (aspirin)	Bisoprolol – candesartan Aspirin – bisoprolol Aspirin – candesartan Aspirin – ciprofloxacin	Monitor Closely / Moderat Monitor Closely / Moderat Monitor Closely / Moderat	Farmakodinamik sinergis Farmakodinamik antagonis Farmakodinamik antagonis	Ciprofloxacin – aspirin Aspirin – candesartan Aspirin – bisoprolol Aspirin – lansoprazole	Moderat Moderat Minor Minor	

112	Tn. S	L	78 Th	CHF DM	Bisoprolol Nospirinal (aspirin) Metformin Candesartan Beraprost	Bisoprolol – candesartan Aspirin – bisoprolol Aspirin – candesartan	<i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i>	Farmakodinamik sinergis Farmakodinamik antagonis Farmakodinamik antagonis	Aspirin – candesartan Aspirin – bisoprolol	Moderat Minor	
113	Ny. SHW	P	64 Th	CHF DM	CPG (clopidogrel) Bisoprolol Atorvastatin Nitrokarf retard (nitroglicerine) ISDN Metformin	Tidak ada interaksi			Atorvastatin – clopidogrel	Moderat	
114	Tn. I	L	54 Th	CHF CAD Stable angina DM	Metformin Glimepiride Furosemide Spironolactone HCT CPG (clopidogrel) Concor (bisoprolol) ISDN	Spironolactone – furosemide Spironolactone – hydrochlorothiazide Bisoprolol – spironolactone Bisoprolol – furosemide	<i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i>		Furosemide – hydrochlorothiazide Furosemide – bisoprolol Hydrochlorothiazide – bisoprolol Spironolactone – bisoprolol	Moderat Moderat Moderat Moderat Moderat	

						Bisoprolol – hydrochlorot hiazide Furosemide – hydrochlorot hiazide Furosemide – hydrochlorot hiazide Metformin – furosemide Hydrochloro thiazide – glimepiride Hydrochloro thiazide – metformin	<i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i> Minor Minor Minor	Farmakodinam ik antagonis Farmakodinam ik antagonis	Furosemide – metformin Hydrochloro thiazide – metformin Spironolactone – metformin Furosemide – glimepiride Hydrochloro thiazide – glimepiride Bisoprolol – glimepiride Metformin – glimepiride Glimepiride – clopidogrel	Moderat Moderat Moderat Moderat Moderat Moderat Minor	
115	Ny. S	P	74 Th	CAD	Candesartan Amlodipine Clonidine Bisoprolol Spironolactone	Clonidine – bisoprolol Bisoprolol – amlodipine	Serius / mayor <i>Monitor Closely / Moderat</i>	Farmakodinam ik sinergis Farmakodinam ik sinergis	Clonidine – bisoprolol Spironolactone – candesartan	Mayor Mayor	

					Furosemide CPG	Bisoprolol – candesartan Bisoprolol – spironolactone Bisoprolol – furosemide Candesartan – furosemide Spironolactone – furosemide	<i>Monitor Closely / Moderat Monitor Closely / Moderat Monitor Closely / Moderat Monitor Closely / Moderat</i>	Farmakodinamik sinergis	Furosemide – bisoprolol Spironolactone – bisoprolol Amlodipine – bisoprolol	Moderat Moderat Moderat	
116	Ny. SM	P	59 Th	CHF IHD	Gemfibrozil Bisoprolol Miniaspi (aspirin) Candesartan Lansoprazole Furosemide Spironolactone	Bisoprolol – candesartan Aspirin – bisoprolol Aspirin – candesartan Aspirin – spironolactone Spironolactone – furosemide Bisoprolol – spironolactone	<i>Monitor Closely / Moderat Monitor Closely / Moderat Monitor Closely / Moderat Monitor Closely / Moderat Monitor Closely / Moderat</i>	Farmakodinamik sinergis Farmakodinamik antagonis Farmakodinamik antagonis Mekanisme interaksi tidak spesifik	Spironolactone – candesartan Furosemide – bisoprolol Spironolactone – bisoprolol Furosemide – lansoprazole Aspirin – candesartan	Mayor Moderat Moderat Moderat Moderat Minor Minor	

						Bisoprolol – furosemide Candesartan – furosemide Aspirin – furosemide	<i>Monitor Closely / Moderat</i> Minor	Farmakodinamik antagonis	Furosemide – aspirin Aspirin – spironolactone Aspirin – bisoprolol Aspirin – lansoprazole	Minor Minor	
117	Tn. CH	L	56 Th	CHF CAD DM	Aspilet (aspirin) Candesartan Bisoprolol Nitrokaf retard (nitroglicerine) Novorapid (insulin aspart) Atorvastatin	Bisoprolol – candesartan Aspirin – bisoprolol Aspirin – candesartan Aspirin – insulin aspart Candesartan – insulin aspart	<i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i> <i>Monitor Closely</i>	Farmakodinamik sinergis Farmakodinamik antagonis Farmakodinamik antagonis Farmakodinamik sinergis Mekanisme interaksi tidak spesifik	Aspirin – candesartan Aspirin – insulin aspart Bisoprolol – insulin aspart Candesartan – insulin aspart Aspirin – nitroglicerine Aspirin – bisoprolol	Moderat Moderat Moderat Minor Minor	
118	Tn. J	L	75 Th	CHF CAD DM	CPG (clopidogrel) Furosemide	Candesartan – furosemide	<i>Monitor Closely / Moderat</i>		Furosemide – metformin	Moderat	

					Simvastatin Metformin Candesartan Mecobalamina	Metformin – furosemide Furosemide – metformin Metformin – mecobalamina	Minor Minor Minor	Mekanisme interaksi tidak spesifik Mekanisme interaksi tidak spesifik			
119	Tn. TGI	L	62 Th	Hipokalemi a CHF	Concor (bisoprolol) Simvastatin Atorvastatin Spironolactone Furosemide Candesartan	Bisoprolol – candesartan Simvastatin – atorvastatin Spironolactone – furosemide Bisoprolol – spironolactone Candesartan – spironolactone Candesartan – furosemide Bisoprolol – furosemide	<i>Monitor Closely /</i> Moderat <i>Monitor Closely /</i> Moderat <i>Monitor Closely /</i> Moderat <i>Monitor Closely /</i> Moderat <i>Monitor Closely /</i> Moderat <i>Monitor Closely /</i> Moderat	Farmakodinamik sinergis	Spironolactone – candesartan Furosemide – bisoprolol Spironolactone – bisoprolol Simvastatin – atorvastatin	Mayor Moderat Moderat Moderat	

120	Tn. s	L	79 Th	CAD CHF	Bisoprolol Diovan (valsartan) CPG (clopidogrel) Atorvastatin ISDN Candesartan	Bisoprolol – candesartan Bisoprolol – valsartan Atorvastatin – valsartan	<i>Monitor Closely / Moderat Monitor Closely / Moderat</i>	Farmakodinam ik sinergis Farmakodinam ik sinergis	Bisoprolol – valsartan Atorvastatin – clopidogrel	Moderat Moderat	
121	Tn. NP	L	67 Th	IHD CHF DM	Metformin Simvastatin Diovan Furosemide Amlodipine Candesartan	Amlodipine – simvastatin Amlodipine – metformin Simvastatin – valsartan Candesartan – furosemide Valsartan – furosemide Furosemide – metformin	Serius / mayor <i>Monitor Closely / Moderat Monitor Closely / Moderat Monitor Closely / Moderat</i> Minor	 Farmakodinam ik antagonis	Amlodipine – simvastatin Furosemide – metformin	Mayor Moderat	
122	Tn. S	L	73 Th	CHF DM IHD	Lansoprazol e Bisoprolol Nitrokaf retard	Bisoprolol – candesartan Lansoprazol e – clopidogrel	<i>Monitor Closely / Moderat Monitor Closely /</i>	Farmakodinam ik sinergis	Furosemide – alprazolam Alprazolam – nitroglicerine	Moderat Moderat Moderat	

					(nitroglicerine) Allopurinol Candesartan Simvastatin Alprazolam Furosemide CPG (clopidogrel) Metformin	Candesartan – furosemide Bisoprolol – furosemide Furosemide – metformin	Moderat <i>Monitor Closely</i> Minor	Mekanisme interaksi tidak spesifik	Furosemide – bisoprolol Alprazolam – bisoprolol Furosemide – metformin Furosemide – lansoprazole Simvastatin – lansoprazole Lansoprazole – clopidogrel Alprazolam – candesartan	Moderat Moderat Moderat Moderat Moderat Moderat	
123	Ny. B	P	61 Th	CHF Hipertensi	Nifedipine Furosemide Spironolactone Bisoprolol CPG (clopidogrel) Simvastatin	Nifedipine – simvastatin Bisoprolol – nifedipine Spironolactone – furosemide	Serius / mayor <i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i>	Farmakodinamik sinergis	Nifedipine – bisoprolol Furosemide – bisoprolol Spironolactone – bisoprolol Nifedipine – simvastatin	Moderat Moderat Moderat Moderat	

						Bisoprolol – spironolactone Bisoprolol – furosemide	<i>Monitor Closely / Moderat</i>				
124	Ny. EL	P	30 Th	CHF Hipertensi	Nifedipine Furosemide Spironolactone Bisoprolol CPG (clopidogrel) Simvastatin	Nifedipine – simvastatin Bisoprolol – nifedipine Spironolactone – furosemide Bisoprolol – spironolactone Bisoprolol – furosemide	Serius / mayor <i>Monitor Closely / Moderat Monitor Closely / Moderat Monitor Closely / Moderat</i>	Farmakodinamik sinergis	Nifedipine – bisoprolol Furosemide – bisoprolol Spironolactone – bisoprolol Nifedipine – simvastatin	Moderat Moderat Moderat Moderat	
125	Ny. NC	P	63 Th	CKD	Furosemide Bisoprolol Omeprazole CPG (clopidogrel) Candesartan	Omeprazole – clopidogrel Bisoprolol – candesartan Candesartan – furosemide	Serius / mayor <i>Monitor Closely / Moderat</i>	Menurunkan efek clopidogrel dengan menghambat enzim hati Farmakodinamik sinergis	Omeprazole – clopidogrel Furosemide – omeprazole Furosemide – bisoprolol	Mayor Moderat Moderat	

						Bisoprolol – furosemide	<i>Monitor Closely / Moderat</i>				
126	Ny. HT	P	58 Th	IHD CHF DM	Trimetazidin Metformin Adalat oros (nifedipine) Allopurinol Nitrokaf retard (nitroglicerine) Miniaspi (aspirin) Atorvastatin	Nifedipine – atorvastatin Nifedipine – metformin	<i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i>	Nifedipine meningkatkan efek atorvastatin dengan mempengaruhi enzim CYP3A4 Farmakodinamik antagonis	Nifedipine – aspirin Nifedipine – nitroglicerine Nifedipine – metformin Nifedipine – atorvastatin Aspirin – nitroglicerine	Moderat Moderat Moderat Moderat Minor	
127	Tn. S	L	88 Th	PPOK CHF	Nospirinal (aspirin) Salbutamol Simvastatin Candesartan Digoxin Alprazolam	Aspirin – candesartan Alprazolam – digoxin Simvastatin – digoxin Aspirin – digoxin Candesartan – digoxin	<i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i>	Farmakodinamik antagonis Mekanisme tidak diketahui	Alprazolam – digoxin Aspirin – digoxin Alprazolam – candesartan Aspirin – candesartan	Moderat Moderat Moderat Moderat	

128	Ny. SR	P	62 Th	CHF IHD	Irbesartan Simvastatin Bisoprolol Nospirinal (aspirin) Lansoprazole	Bisoprolol – irbesartan Aspirin – bisoprolol Aspirin – irbesartan	<i>Monitor Closely / Moderat Monitor Closely / Moderat</i>	Farmakodinam ik sinergis Farmakodinam ik antagonis Farmakodinam ik antagonis	Simvastatin – lansoprazole Aspirin – irbesartan Aspirin – bisoprolol Aspirin – lansoprazole	Moderat Moderat Minor Minor	
129	Ny. M	P	80 Th	CHF Hipertensi	Amlodipine Simvastatin Nospirinal (aspirin) Bisoprolol Candesartan	Amlodipine – simvastatin Bisoprolol – amlodipine Bisoprolol – candesartan Aspirin – bisoprolol Aspirin – candesartan	Serius / mayor <i>Monitor Closely / Moderat Monitor Closely / Moderat Monitor Closely / Moderat</i>	Amlodipine meningkatkan kadar simvastatin Farmakodinam ik sinergis Farmakodinam ik sinergis Farmakodinam ik antagonis Farmakodinam ik antagonis	Amlodipine – simvastatin Aspirin – amlodipine Amlodipine – bisoprolol Aspirin – candesartan Aspirin – bisoprolol	Mayor Moderat Moderat Moderat Minor	
130	Ny. MN	P	57 Th	CHF DM	Alprazolam Nospirinal (aspirin) Simvastatin Candesartan	Bisoprolol – candesartan Aspirin – bisoprolol	<i>Monitor Closely / Moderat</i>	Farmakodinam ik sinergis Farmakodinam ik antagonis	Alprazolam – bisoprolol Alprazolam – candesartan	Moderat Moderat Moderat	

					Bisoprolol Metformin	Aspirin – candesartan	<i>Monitor Closely / Moderat</i>	Farmakodinam ik antagonis	Aspirin – candesartan Aspirin – bisoprolol	Minor	
131	Ny. S	P	54 Th	CHF IHD	Nospirinal (aspirin) Simvastatin Bisoprolol Candesartan Nitrokaf retard (nitrogliverin)	Bisoprolol – candesartan Aspirin – bisoprolol Aspirin – candesartan	<i>Monitor Closely / Moderat Monitor Closely / Moderat</i>	Farmakodinam ik sinergis Farmakodinam ik antagonis Farmakodinam ik antagonis	Aspirin – candesartan Aspirin – nitroglicerine Aspirin – bisoprolol	Moderat Minor Minor	
132	Ny. P	P	68 Th	Stable Angina CHF	Candesartan Lansoprazol e Simvastatin Miniaspi (aspirin) Clopidogrel	Aspirin – clopidogrel Aspirin – candesartan Lansoprazol e – clopidogrel	<i>Monitor Closely / Moderat Monitor Closely / Moderat</i>	Farmakodinam ik sinergis Farmakodinam ik antagonis	Simvastatin – lansoprazole Aspirin – clopidogrel Lansoprazol e – clopidogrel Aspirin – candesartan Aspirin – lansoprazole	Moderat Moderat Moderat Moderat Minor	

133	Ny. HNC	P	43 Th	CHF Hiperglikemia	Ondansetron Simvastatin Allopurinol Bisoprolol	Tidak ada interaksi					
134	Ny. S	P	70 Th	CHF Hipertensi	Alprazolam Irbesartan Amlodipine Beraprost Furosemide Simvastatin	Amlodipine – simvastatin Irbesartan – furosemide	Serius / mayor <i>Monitor Closely / Moderat</i>	Amlodipine meningkatkan kadar simvastatin	Amlodipine – simvastatin Furosemide – alprazolam Alprazolam – amlodipine Alprazolam – irbesartan	Mayor Moderat Moderat Moderat	
135	Tn. SS	L	48 Th	CHF DM	CPG (clopidogrel) Atorvastatin Ramipril Metformin Allopurinol Alprazolam	Ramipril – metformin	<i>Monitor Closely / Moderat</i>	Ramipril meningkatkan toksisitas metformin melalui mekanisme interaksi yang tidak ditentukan	Allopurinol – ramipril Alprazolam – ramipril Ramipril – metformin Atorvastatin – clopidogrel	Mayor Moderat Moderat Moderat	
136	Ny. H	P	66 Th	CHF IHD Hipertensi	Irbesartan Amlodipine Furosemide	Bisoprolol – irbesartan	<i>Monitor Closely / Moderat</i>	Farmakodinam ik sinergis	Furosemide – alprazolam	Moderat Moderat	

					Miniaspi Bisoprolol Lansoprazol e Alprazolam	Aspirin – bisoprolol Bisoprolol – amlodipine Aspirin – irbesartan Irbesartan – furosemide Bisoprolol – furosemide Aspirin – furosemide	<i>Monitor Closely</i> / Moderat <i>Monitor Closely</i> / Moderat <i>Monitor Closely</i> / Moderat Minor	Farmakodinam ik antagonis Farmakodinam ik sinergis Farmakodinam ik antagonis Farmakodinam ik antagonis	Alprazolam – amlodipine Aspirin – amlodipine Furosemide – bisoprolol Alprazolam – bisoprolol Amlodipine – bisoprolol Furosemide – lansoprazole Alprazolam – irbesartan Aspirin – irbesartan Furosemide – aspirin Aspirin – bisoprolol Aspirin – lansoprazole	Moderat Moderat Moderat Moderat Moderat Moderat Minor Minor Minor	
137	Tn. S	L	66 Th	CHF	Nospirinal (aspirin) Simvastatin	Tidak ada interaksi		Simvastatin – lansoprazole	Moderat		

					Alprazolam Salbutamol Lansoprazole				Aspirin – lansoprazole	Minor	
138	Tn. S	L	67 Th	CHF IHD	Omeprazole Furosemide Simvastatin Miniaspi (aspirin) Candesartan	Aspirin – candesartan Candesartan – furosemide Aspirin – furosemide	<i>Monitor Closely / Moderat</i> Minor	Farmakodinam ik antagonis Farmakodinam ik antagonis	Furosemide – omeprazole Omeprazole – simvastatin Aspirin – candesartan Furosemide – aspirin Aspirin – omeprazole	Moderat Moderat Moderat Minor Minor	
139	Ny. B	P	54 Th	CHF	Miniaspi (aspirin) Simvastatin ISDN Furosemide Candesartan	Aspirin – candesartan Candesartan – furosemide Aspirin – furosemide	<i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i> Minor	Farmakodinam ik antagonis Farmakodinam ik antagonis	Aspirin – candesartan Furosemide – aspirin	Moderat Minor	
140	Ny. S	P	65 Th	CHF Hipertensi	Beraprost Mecobalamin	Amlodipine – simvastatin	Serius / mayor	Amlodipine meningkatkan	Amlodipine – simvastatin	Mayor	

					Simvastatin Irbesartan Nospirinal (aspirin) Lansoprazole Amlodipine	Aspirin – irbesartan Lansoprazole – mecobalamine Aspirin – mecobalamine	<i>Monitor Closely /</i> Moderat Minor Minor	kadar simvastatin Farmakodinamik antagonis	Aspirin – amlodipine Simvastatin – lansoprazole Aspirin – irbesartan Aspirin – lansoprazole Lansoprazole – mecobalamine	Moderat Moderat Moderat Minor Minor	
141	Ny.S M	P	68 Th	CKD	Simvastatin Furosemide Amlodipine Candesartan Bisoprolol	Amlodipine – simvastatin Bisoprolol – amlodipine – bisoprolol – candesartan Bisoprolol – furosemide Candesartan – furosemide	Serius / mayor <i>Monitor Closely /</i> Moderat <i>Monitor Closely /</i> Moderat <i>Monitor Closely</i>	 Farmakodinamik sinergis Farmakodinamik sinergis	Amlodipine – simvastatin Furosemide – bisoprolol Bisoprolol – amlodipine	Mayor Moderat Moderat	

142	Tn. YB	L	65 Th	CHD IHD	Miniaspi (aspirin) Alprazolam Simvastatin Bisoprolol Candesartan Furosemide	Bisoprolol – candesartan Aspirin – bisoprolol Aspirin – candesartan Candesartan – furosemide Bisoprolol – furosemide Aspirin – furosemide	<i>Monitor Closely /</i> Moderat <i>Monitor Closely /</i> Moderat Monitor closely/ moderat Minor	Farmakodinamik sinergis Farmakodinamik antagonis Farmakodinamik antagonis Farmakodinamik antagonis	Furosemide – alprazolam Furosemide – bisoprolol Alprazolam – bisoprolol Alprazolam – candesartan Aspirin – candesartan Furosemide – aspirin Aspirin – bisoprolol	Moderat Moderat Moderat Moderat Minor Minor	
143	Tn.TI	L	58 Th	CHF Dislipidemia	Bisoprolol Braxidin (chlordiazepoxide/ clidinium) Lansoprazole Candesartan Nospirinal	Bisoprolol – candesartan Aspirin – bisoprolol	Monitor	Farmakodinamik sinergis Farmakodinamik antagonis	Chlordiazepoxide – bisoprolol Aspirin – candesartan Chlordiazepoxide – candesartan Aspirin – bisoprolol	Moderat Moderat Moderat Minor	

									Aspirin – lansoprazole	Minor	
144	Ny.M	P	64 Th	HHD CHF	Beraprost Bisoprolol Candesartan Lansoprazole Simvastatin	Bisoprolol – candesartan	Monitor	Farmakodinamik sinergis	Simvastatin – lansoprazole	Moderat	
145	Ny. Y	P	86 Th	CHF Chepalgia	Nospirinal (aspirin) Candesartan Bisoprolol Simvastatin Allopurinol	Bisoprolol – candesartan Aspirin – bisoprolol Aspirin – candesartan	Monitor	Farmakodinamik sinergis Farmakodinamik antagonis Farmakodinamik antagonis	Aspirin – candesartan Aspirin – bisoprolol	Moderat Minor	
146	Tn. F	L	44 Th	CHF IHD	Cefixime Bisoprolol Candesartan Simvastatin Furosemide	Bisoprolol – candesartan Cefixime – furosemide	<i>Monitor Closely /</i> Moderat Minor	Farmakodinamik sinergis Farmakodinamik sineergis	Furosemide – cefixime Furosemide – bisoprolol	Moderat Moderat	
147	Ny. K	P	81 Th	CHF Hipertensi	Miniaspi (aspirin) Simvastatin Amlodipin Bisoprolol	Amlodipine – simvastatin Bisoprolol – amlodipine Aspirin – bisoprolol	Serius <i>Monitor Closely /</i> Moderat	Farmakodinamik sinergis Farmakodinamik antagonis	Amlodipine – simvastatin Aspirin – amlodipine Amlodipine – bisoprolol	Mayor Moderat Moderat	

									Aspirin – bisoprolol	Minor	
148	Tn. P	L	59 Th	IHD Hipokalemi a	CPG (clopidogrel) Concor (bisoprolol) Candesartan Amlodipin Furosemide	Bisoprolol – candesartan Bisoprolol – amlodipine Candesartan furosemide	<i>Monitor Closely / Moderat</i>	Farmakodinamik sinergis Farmakodinamik sinergis	Furosemide – bisoprolol Amlodipine – bisoprolol	Moderat Moderat	
149	Ny. S	P	64 Th	IHD Hiperkalemi a	Nitrokaf retard (nitrogliserin) Miniaspi (aspirin) Simvastatin Candesartan Bisoprolol Furosemide	Bisoprolol – candesartan Aspirin – bisoprolol Aspirin – candesartan Aspirin – furosemide	<i>Monitor Closely / Moderat</i> Minor	Farmakodinamik sinergis Farmakodinamik antagonis Farmakodinamik antagonis Farmakodinamik antagonis	Furosemide – bisoprolol Aspirin – candesartan Furosemide – aspirin Aspirin – nitrogliserin Aspirin – bisoprolol	Moderat Moderat Minor Minor Minor	
150	Ny. S	P	57 Th	CHF IHD	Furosemide Simvastatin Miniaspi (aspirin) Candesartan Bisoprolol Alprazolam	Bisoprolol – candesartan Aspirin – bisoprolol Aspirin – candesartan	<i>Monitor Closely / Moderat</i>	Farmakodinamik sinergis Farmakodinamik antagonis Farmakodinamik antagonis	Furosemide – alprazolam Furosemide – bisoprolol Alprazolam – bisoprolol	Moderat Moderat Moderat Moderat	

						Aspirin – furosemide	Minor	Farmakodinamik antagonis	Alprazolam – candesartan Aspirin candesartan Furosemide – aspirin Aspirin – bisoprolol	Moderat Minor Minor	
151	Ny. D	P	78 Th	CAD Stable Angina CHF	CPG (clopidogrel) Amlodipin Candesartan Bisoprolol Simvastatin ISDN Lansoprazole	Amlodipine – simvastatin Bisoprolol – amlodipine Bisoprolol – candesartan Lansoprazole – clopidogrel	Serius / mayor <i>Monitor Closely / Moderat</i>	 Farmakodinamik sinergis Farmakodinamik sinergis	Amlodipine – simvastatin Amlodipine – bisoprolol Simvastatin – lansoprazole Lansoprazole – clopidogrel	Mayor Moderat Moderat Moderat	
152	Ny. H	P	68 Th	ACS VAP	Aspilet (aspirin) CPG (clopidogrel) Candesartan Atorvastatin	Bisoprolol – candesartan Aspirin – bisoprolol	<i>Monitor Closely / Moderat</i>	Farmakodinamik sinergis Farmakodinamik antagonis	Aspirin – clopidogrel Atorvastatin – clopidogrel	Moderat Moderat Moderat	

					Nitrokaf retard (nitrogliserin) 154Concor (bisoprolol) Loxadin	Aspirin – clopidogrel Aspirin – candesartan		Farmakodinam ik sinergis Farmakodinam ik antagonis	Aspirin – candesartan Aspirin – nitroglicerine Aspirin – bisoprolol	Minor Minor	
153	Ny. TSL	P	77 Th	CHF	Atorvastatin Allopurinol Nitrokaf retard (nitroglicerine) Meloxicam Candesartan Clopidogrel Digoxin	Candesartan – meloxicam Clopidogrel – meloxicam Atorvastatin – digoxin	<i>Monitor Closely / Moderat</i>	Farmakodinam ik antagonis Farmakodinam ik sinergis	Candesartan – meloxicam Digoxin – atorvastatin Atorvastatin – clopidogrel Digoxin – meloxicam Clopidogrel – meloxicam	Moderat Moderat Moderat Moderat Moderat	
154	Ny. TSL	P	65 Th	IHD CHF Hipertensi	Aspirin Amlodipin CPG (clopidogrel) Bisoprolol Candesartan ISDN Lansoprazol e	Aspirin – clopidogrel Aspirin – candesartan Lansoprazol e – clopidogrel	<i>Monitor Closely / Moderat</i>	Farmakodinam ik sinergis Farmakodinam ik antagonis	Aspirin – amlodipine Aspirin – clopidogrel Aspirin – candesartan Lansoprazol e – clopidogrel	Moderat Moderat Moderat Moderat Minor	

									Aspirin – lansoprazole		
155	Ny. NRW	P	44 Th	IHD CHF	Nospirinal (aspirin) Simvastatin Bisoprolol Nitrokaf retard (nitroglicerine) Allopurinol	Aspirin – bisoprolol	<i>Monitor Closely / Moderat</i>	Farmakodinam ik antagonis	Aspirin – bisoprolol Aspirin – nitroglicerine	Minor Minor	
156	Ny. RP	P	55 Th	CHF	Mecobalamin Sucralfate KSR (potassium chloride) Spironolactone Lansoprazole Simvastatin CPG (clopidogrel)	Spironolactone – potassium chloride Lansoprazole – clopidogrel Sucralfate – lansoprazole	Serius / mayor <i>Monitor Closely</i> Minor		Spironolactone – potassium chloride Sucralfate – lansoprazole Simvastatin – lansoprazole Lansoprazole – clopidogrel	Mayor Moderat Moderat Moderat	
157	Ny. RB	P	73 Th	CHF	Nospirinal (aspirin) Simvastatin Candesartan	Bisoprolol – candesartan Aspirin – bisoprolol	<i>Monitor Closely / Moderat</i>	Farmakodinam ik sinergis Farmakodinam ik antagonis	Aspirin – candesartan	Moderat Minor	

					Bisoprolol	Aspirin – candesartan		Farmakodinam ik antagonis	Aspirin – bisoprolol		
158	Tn . M	L	56 Th	CHF	Alprazolam Nitrokaf retard (nitroglicerine) Lansoprazole Miniaspi (aspirin) Bisoprolol Spironolactone	Aspirin – bisoprolol Aspirin – spironolactone	<i>Monitor Closely / Moderat</i>	Farmakodinam ik antagonis	Alprazolam – nitroglicerine Alprazolam – spironalctone Alprazolam – bisoprolol Spironalctone – bisoprolol Aspirin – nitroglicerine Aspirin – spironolactone Aspirin – bisoprolol Aspirin – lansoprazole	Moderat Moderat Moderat Moderat Minor Minor Minor Minor	
159	Ny. S	P	69 Th	CHF	Gemfibrozil Nospirinal (aspirin)	Aspirin – bisoprolol	<i>Monitor Closely / Moderat</i>	Farmakodinam ik antagonis	Alprazolam – nitroglicerine	Moderat Moderat	

					Bisoprolol Alprazolam Nitrokaf retard (nitroglicerine)				Alprazolam – bisoprolol Aspirin – nitroglicerine Aspirin – bisoprolol	Minor Minor	
160	Ny. S	P	57 Th	CHF Hipertensi	Farsifent (ibuprofen) Candesartan Amlodipine Bisoprolol Simvastatin Allopurinol	Amlodipine – simvastatin Bisoprolol – amlodipine Bisoprolol – candesartan Ibuprofen – bisoprolol Ibuprofen – candesartan	Serius / mayor <i>Monitor Closely / Moderat</i>	Farmakodinam ik sinergis Farmakodinam ik sinergis Farmakodinam ik antagonis Farmakodinam ik antagonis	Amlodipine – simvastatin Ibuprofen – amlodipine Ibuprofen – bisoprolol Ibuprofen – candesartan Amlodipine – bisoprolol	Mayor Moderat Moderat Moderat Moderat	
161	Tn. SKT	L	66 Th	CHF Pneumonia	Furosemide Spironolactone Bisoprolol Nitrokaf retard (nitroglicerine)	Bisoprolol – spironolactone Spironolactone – furosemide Bisoprolol – furosemide	<i>Monitor Closely / Moderat Monitor Closely / Moderat</i>		Furosemide – bisoprolol Spironolactone – bisoprolol Furosemide – lansoprazole	Moderat Moderat Moderat	

					Lansoprazole						
162	Tn. M	L	63 Th	CHF HHD Hipokalemi a	Candesartan Amlodipine Simvastatin Bisoprolol	Amlodipine – simvastatin Amlodipine – bisoprolol Bisoprolol – candesartan	Serius / mayor <i>Monitor Closely</i> / Moderat	Farmakodinamik sinergis Farmakodinamik sinergis	Amlodipine – simvastatin Amlodipine – bisoprolol	Mayor Moderat	
163	Ny. RRS	P	65 Th	CAD DM	Simvastatin Candesartan Amlodipine CPG (clopidogrel) Bisoprolol Metformin	Amlodipine – simvastatin Amlodipine - metformin Amlodipine – bisoprolol Bisoprolol – candesartan	Serius / Mayor Monitor closely/ Moderat	Farmakodinamik antagonis Farmakodinamik sinergis Farmakodinamik sinergis	Amlodipine – simvastatin Amlodipine – bisoprolol	Mayor Moderat	
164	Tn. VS	L	80 Th	CHF	Miniaspi (aspirin) Simvastatin Bisoprolol Nitrokaf retard (nitroglicerine) Alprazolam	Aspirin – bisoprolol	<i>Monitor Closely</i> / Moderat	Farmakodinamik antagonis	Alprazolam – nitroglicerine Alprazolam – bisoprolol Aspirin – nitroglicerine Aspirin – bisoprolol	Moderat Moderat Minor Minor	

165	Ny. M	P	61 Th	CHF CAD DM	Metformin Lansoprazole ISDN Ramipril Miniaspi Spironolactone	Aspirin – ramipril Ramipril – spironolactone Ramipril – metformin Aspirin – spironolactone	Serius / mayor <i>Monitor Closely / Moderat Monitor Closely / Moderat</i>	Farmakodinamik antagonis Farmakodinamik sinergis Tidak diketahui Tidak diketahui	Ramipril – spironolactone Aspirin – ramipril ISDN – ramipril Spironolactone – metformin Ramipril – metformin Aspirin – spironolactone Aspirin – lansoprazole	Mayor Moderat Moderat Moderat Moderat Minor Minor	
166	Tn. HS	L	63 Th	CHF IHD DM	Metformin Furosemide Spironolactone Candesartan Allopurinol mecobalamin	Spironolactone – furosemide Candesartan – spironolactone Candesartan – furosemide	<i>Monitor Closely / Moderat Monitor Closely / Moderat</i> Minor		Spironolactone – candesartan Furosemide – metformin Spironolactone – metformin	Mayor Moderat Moderat	

						Metformin – furosemide Metformin – mecobalami n	Minor				
167	Tn. SS	L	74 Th	CHF IHD	Spironolactone Furosemide Simvastatin Bisoprolol Miniaspi (aspirin) Candesartan Lansoprazole	Bisoprolol – candesartan Aspirin – bisoprolol Aspirin – candesartan Aspirin – spironolactone Aspirin – furosemide	Monitor Closely / Moderat Monitor Closely / Moderat Monitor Closely / Moderat Minor	Farmakodinamik sinergis Farmakodinamik antagonis Farmakodinamik antagonis Tidak diketahui Farmakodinamik antagonis	Spironolactone – candesartan Furosemide – bisoprolol Spironolactone – bisoprolol Furosemide – lansoprazole Simvastatin – lansoprazole Aspirin – candesartan Furosemide – aspirin	Mayor Moderat Moderat Moderat Moderat Moderat Minor Minor Minor Minor	

									Aspirin – spironolactone Aspirin – bisoprolol Aspirin – lansoprazole		
168	Tn. SS	L	79 Th	NSTEMI	ISDN Furosemide Irbesartan Nospirinal (aspirin) Simvastatin Bisoprolol Alprazolam	Bisoprolol – irbesartan Aspirin – bisoprolol Aspirin – irbesartan Irbesrtan – furosemide Aspirin – furosemide	<i>Monitor Closely / Moderat Monitor Closely / Moderat Monitor closely/ Moderat</i> Minor	Farmakodinam ik sinergis Farmakodinam ik antagonis Farmakodinam ik antagonis Farmakodinam ik antagonis	Furosemide – alprazolam Alprazolam – ISDN Furosemide – bisoprolol Alprazolam – bisoprolol Alprazolam – irbesartan Aspirin – irbesartan Furosemide – aspirin Aspirin – bisoprolol	Moderat Moderat Moderat Moderat Moderat Moderat Minor Minor	
169	Tn. S	L	69 Th	CKD Hipertensi	Simvatstain Furosemide Amlodipine Candesartan	Amlodipine – simvastatin	Serius / mayor		Amlodipine – simvastatin	Mayor Moderat	

					Bisoprolol	Bisoprolol – amlodipine – bisoprolol – candesartan Bisoprolol – furosemide Candesartan – furosemide	<i>Monitor Closely / Moderat Monitor Closely / Moderat Monitor Closely</i>	Farmakodinam ik sinergis Farmakodinam ik sinergis	Furosemide – bisoprolol Bisoprolol – amlodipine	Moderat	
170	Tn. DR	L	60 Th	CHD IHD	Miniaspi (aspirin) Alprazolam Simvastatin Bisoprolol Candesartan Furosemide	Bisoprolol – candesartan Aspirin – bisoprolol Aspirin – candesartan Candesartan – furosemide Bisoprolol – furosemide Aspirin – furosemide	<i>Monitor Closely / Moderat Monitor Closely / Moderat Monitor closely/ moderat</i> Minor	Farmakodinam ik sinergis Farmakodinam ik antagonis Farmakodinam ik antagonis Farmakodinam ik antagonis	Furosemide – alprazolam Furosemide – bisoprolol Alprazolam – bisoprolol Alprazolam – candesartan Aspirin – candesartan Furosemide – aspirin Aspirin – bisoprolol	Moderat Moderat Moderat Moderat Moderat Minor Minor	
171	Ny. WSR	P	62 Th	CKD	Bisoprolol Fenofibrate Lansoprazol e	Aspirin – bisoprolol	<i>Monitor Closely / Moderat</i>	Farmakodinam ik antagonis Tidak diketahui	Spironolacto ne – bisoprolol	Moderat Moderat	

					Spironolactone Nitrokarf retard (nitroglycerin) Miniaspirin (aspirin)	Aspirin – spironolactone Bisoprolol – spironolactone	<i>Monitor Closely / Moderat</i>		Lansoprazole – fenofibrate Aspirin – nitroglycerin Aspirin – spironolactone Aspirin – bisoprolol Aspirin – lansoprazole	Minor Minor Minor Minor	
172	Tn. MK	L	65 Th	CHF IHD	Uperio (sacubitril/valsartan) Beraprost Simvastatin Nospirinal (aspirin) Lansoprazole Mecobalamine	Aspirin – sacubitril/valsartan Simvastatin – sacubitril/valsartan Lansoprazole – mecobalamine Aspirin – mecobalamine	<i>Monitor Closely / Moderat Monitor Closely / Moderat Minor Minor</i>	Farmakodinamik antagonis	Simvastatin – lansoprazole Aspirin – sacubitril/valsartan Simvastatin – sacubitril/valsartan Aspirin – lansoprazole Lansoprazole –	Moderat Moderat Moderat Minor Minor	

									mecobalami n		
173	Ny. SD	P	43 Th	CHF IHD	Candesartan Furosemide Miniaspi Nospirinal (aspirin) Simvastatin Bisoprolol	Bisoprolol – candesartan Aspirin – bisoprolol Aspirin – candesartan Candesartan – furosemide Bisoprolol – furosemide Aspirin – furosemide	<i>Monitor</i> <i>Closely</i> / Moderat <i>Monitor</i> <i>Closely</i> / Moderat <i>Monitor</i> <i>Closely</i> / Moderat Minor	Farmakodinam ik sinergis Farmakodinam ik antagonis Farmakodinam ik antagonis Farmakodinam ik antagonis	Furosemide – bisoprolol Aspirin – candesartan Furosemide – aspirin Aspirin – bisoprolol	Moderat Moderat Minor Minor	
174	Ny. S	P	66 Th	CHF HHD	Miniaspi (aspirin) Bisoprolol Candesartan Atorvastatin Lansoprazol e	Bisoprolol – candesartan Aspirin – bisoprolol Aspirin – candesartan	<i>Monitor</i> <i>Closely</i> / Moderat <i>Monitor</i> <i>Closely</i> / Moderat	Farmakodinam ik sinergis Farmakodinam ik antagonis Farmakodinam ik antagonis	Lansoprazol e – atorvastatin Aspirin – candesartan Aspirin – bisoprolol Aspirin – lansoprazole	Moderat Moderat Minor Minor	
175	Tn. H	L	62 Th	CAD Dislipidemi a	CPG (clopidogrel)	Aspirin – clopidogrel	<i>Monitor</i> <i>Closely</i> / Moderat	Farmakodinam ik sinergis	Simvastatin – lansoprazole	Moderat Moderat	

					Lansoprazole Aspilet (aspirin) Simvastatin	Lansoprazole – clopidogrel			Aspirin – clopidogrel Lansoprazole – clopidogrel Aspirin – lansoprazole	Moderat Minor	
176	Tn. S	L	48 Th	CHF IHD	Candesartan Simvastatin Bisoprolol Nospirinal (aspirin) Nitrokaf retard (nitroglicerine) Lansoprazole	Bisoprolol – candesartan Aspirin – bisoprolol Aspirin – candesartan	<i>Monitor</i> <i>Closely</i> / Moderat <i>Monitor</i> <i>Closely</i> / Moderat	Farmakodinamik sinergis Farmakodinamik antagonis Farmakodinamik antagonis	Simvastatin – lansoprazole Aspirin – candesartan Aspirin – nitroglicerine Aspirin – bisoprolol Aspirin – lansoprazole	Moderat Moderat Minor Minor Minor	
177	Tn. M	L	56 Th	CHF IHD	Furosemide Simvastatin Miniaspi (aspirin) Candesartan Bisoprolol Alprazolam	Bisoprolol – candesartan Aspirin – bisoprolol Aspirin – candesartan	<i>Monitor</i> <i>Closely</i> / Moderat <i>Monitor</i> <i>Closely</i> / Moderat Minor	Farmakodinamik sinergis Farmakodinamik antagonis Farmakodinamik antagonis	Furosemide – alprazolam Furosemide – bisoprolol Alprazolam – bisoprolol	Moderat Moderat Moderat Moderat	

						Aspirin – furosemide		Farmakodinam ik antagonis	Alprazolam – candesartan Aspirin candesartan Furosemide – aspirin Aspirin – bisoprolol	Moderat Minor Minor	
178	Tn. AS	L	66 Th	CHF Chepalgia DM	Metformin Simvastatin Bisoprolol Nospirinal (aspirin) Candesartan Lansoprazol e	Bisoprolol – candesartan Aspirin – bisoprolol Aspirin – candesartan	<i>Monitor Closely / Moderat Monitor Closely / Moderat</i>	Farmakodinam ik sinergis Farmakodinam ik antagonis Farmakodinam ik antagonis	Simvastatin – lansoprazole Aspirin – candesartan Aspirin – bisoprolol DMAspirin – lansoprazole	Moderat Moderat Minor Minor	
179	Tn. S	L	52 Th	CHF	Beraprost Miniaspi (aspirin) Bisoprolol Lansoprazol e Allopurinol	Aspirin – bisoprolol	<i>Monitor Closely / Moderat</i>	Farmakodinam ik antagonis	Lansoprazol e – atorvastatin Aspirin – bisoprolol	Moderat Minor Minor	

					Atorvastatin				Aspirin – lansoprazole		
180	Tn. S	L	65 Th	CHF	Lansoprazole Simvastatin Bisoprolol Candesartan Nospirinal (aspirin)	Bisoprolol – candesartan Aspirin – bisoprolol Aspirin – candesartan	<i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i>	Farmakodinamik sinergis Farmakodinamik antagonis Farmakodinamik antagonis	Simvastatin – lansoprazole Aspirin – candesartan Aspirin – bisoprolol Aspirin – lansoprazole	Moderat Moderat Minor Minor	
181	Ny. SM	P	51 Th	Aritmia CHF	Furosemide Lapisiv Lansoprazole Simvastatin Candesartan Bisoprolol	Bisoprolol – candesartan Bisoprolol – furosemide Candesartan – furosemide	<i>Monitor Closely / Moderat</i> <i>Monitor closely / Moderat</i> <i>Monitor Closely / Moderat</i>	Farmakodinamik sinergis	Furosemide – bisoprolol Furosemide – lansoprazole Simvastatin – lansoprazole	Moderat Moderat Moderat	
182	Tn. H	L	62 Th	Aritmia Hipokalemi a CHF	Nospirinal (aspirin) Bisoprolol Lansoprazole Concor	Aspirin – bisoprolol	<i>Monitor Closely / Moderat</i>	Farmakodinamik antagonis	Aspirin – bisoprolol Aspirin – lansoprazole	Minor Minor	

183	Tn. SR	L	61 Th	IHD CHF	Nitrokaf retard (nitrogliserin) Simvastatin Bisoprolol Miniaspi (aspirin) Candesartan Beraprost	Bisoprolol – candesartan Aspirin – bisoprolol Aspirin – candesartan	<i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i>	Farmakodinamik sinergis Farmakodinamik antagonis Farmakodinamik antagonis	Aspirin – candesartan Aspirin – nitrogliserin Aspirin – bisoprolol	Moderat Minor Minor	
184	Tn. S	L	65 Th	CHF	Uresix (furosemide) Simvastatin Lansoprazole Nospirinal (aspirin)	Aspirin – furosemide Aspirin – furosemide	<i>Monitor Closely / Moderat</i> Minor	 Farmakodinamik antagonis	Furosemide – lansoprazole Simvastatin – lansoprazole Furosemide – aspirin Aspirin – lansoprazole	Moderat Moderat Minor Minor	
185	Tn. MT	L	82 Th	CHF Hipertensi	Lansoprazole Amlodipine Bisoprolol Candesartan Simvastatin	Amlodipine – simvastatin Bisoprolol – amlodipine Bisoprolol – candesartan	Serius <i>Monitor Closely / Moderat</i>	 Farmakodinamik sinergis Farmakodinamik sinergis	Amlodipine – simvastatin Amlodipine – bisoprolol	Mayor Moderat Moderat	

									Simvastatin – lansoprazole		
186	Ny. D	P	53 Th	CAD DM	Glibenklami de Metformin Bisoprolol Atorvastatin Mecobalami n	Tidak ada interaksi			Glyburide / metformin – bisoprolol	Moderat	
187	Tn. S	L	63 Th	CHF IHD	Candesartan Simvastatin Bisoprolol Nospirinal (aspirin) Nitrokaf retard (nitroglicer in) Lansoprazol e	Bisoprolol – candesartan Aspirin – bisoprolol Aspirin – candesartan	<i>Monitor Closely / Moderat Monitor Closely / Moderat</i>	Farmakodinam ik sinergis Farmakodinam ik antagonis Farmakodinam ik antagonis	Simvastatin – lansoprazole Aspirin – candesartan Aspirin – nitroglicer in Aspirin – bisoprolol Aspirin – lansoprazole	Moderat Moderat Minor Minor Minor	
188	Ny. PP	P	60 Th	CAD Dislipidemi a	Candesartan Amlodipine Simvastatin Miniaspi (aspirin) Allopurinol	Amlodipine – simvastatin Aspirin – candesartan	Serius / mayor <i>Monitor Closely / Moderat</i>	Farmakodinam ik antagonis	Amlodipine – simvastatin Aspirin – amlodipine	Mayor Moderat Moderat	

									Aspirin – candesartan		
189	Tn. SHS	L	69 Th	CHF IHD DM	Nospirinal (aspirin) Simvastatin Bisoprolol Candesartan Nitrokaf retard (nitroglicerín) Metformin	Bisoprolol – candesartan Aspirin – bisoprolol Aspirin – candesartan	<i>Monitor Closely / Moderat Monitor Closely / Moderat</i>	Farmakodinam ik sinergis Farmakodinam ik antagonis Farmakodinam ik antagonis	Aspirin – candesartan Aspirin – nitroglicerín Aspirin – bisoprolol	Moderat Minor Minor	
190	Ny. S	P	81 Th	CHF IHD	Uperio (sacubitril/valsartan) Simvastatin Bisoprolol Lansoprazole Nospirinal (aspirin)	Aspirin – bisoprolol Aspirin – sacubitril/valsartan Bisoprolol – sacubitril/valsartan Simvastatin – sacubitril/valsartan	<i>Monitor Closely / Moderat Monitor Closely / Moderat Monitor Closely / Moderat</i>	Farmakodinam ik antagonis Farmakodinam ik antagonis Farmakodinam ik sinergis	Simvastatin – lansoprazole Aspirin – sacubitril/valsartan Bisoprolol – sacubitril/valsartan Simvastatin – sacubitril/valsartan	Moderat Moderat Moderat Moderat Minor Minor	

						Lansoprazole – mecobalamine Aspirin – mecobalamine	Minor		Aspirin – bisoprolol Aspirin – lansoprazole Lansoprazole – mecobalamine	Minor Minor	
193	Ny. K	P	70 Th	CHF	Simvastatin Bisoprolol Lansoprazole Nospirinal (aspirin)	Aspirin – bisoprolol	<i>Monitor Closely / Moderat</i>	Farmakodinamik antagonis	Simvastatin – lansoprazole Aspirin – bisoprolol Aspirin – lansoprazole	Moderat Minor Minor	
194	Ny. M	P	62 Th	IHD CHF	Alprazolam Atorvastatin Bisoprolol Candesartan Miniaspi (aspirin) Furosemide Spironolactone	Bisoprolol – candesartan Aspirin – bisoprolol Aspirin – spironolactone Aspirin – candesartan Spironolactone – furosemide	<i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i> Minor	Farmakodinamik sinergis Farmakodinamik antagonis Tidak diketahui Farmakodinamik antagonis	Spironolactone – candesartan Furosemide – alprazolam Alprazolam - spironolactone Furosemide – bisoprolol	Mayor Moderat Moderat Moderat Moderat	

						Aspirin – furosemide		Farmakodinam ik antagonis	Alprazolam – bisoprolol Spironolacto ne – bisoprolol Alprazolam – candesartan Aspirin – candesartan Furosemide – aspirin Aspirin – spironolacto ne Aspirin – bisoprolol	Moderat Moderat Minor Minor Minor	
195	Ny. T	P	52 Th	CHF	Nospirinal (aspirin) Simvastatin Bisoprolol Lansoprazol e	Aspirin – bisoprolol	<i>Monitor Closely / Moderat</i>	Farmakodinam ik antagonis	Simvastatin – lansoprazole Aspirin – bisoprolol Aspirin – lansoprazole	Moderat Minor Minor	
196	Tn. K	L	62 Th	CHF	Spironolacto ne	Digoxin – bisoprolol	Serius / mayor		Furosemide – digoxin	Moderat	

					Digoxin Bisoprolol Furosemide	Bisoprolol – digoxin Furosemide – digoxin Spironolactone – digoxin Bisoprolol – spironolactone Spironolactone – furosemide Bisoprolol – furosemide	<i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i>	Farmakodinamik sinergis Farmakodinamik sinergis	Furosemide – bisoprolol Digoxin – bisoprolol Spironolactone – bisoprolol Digoxin – spironolactone	Moderat Moderat Moderat Minor	
197	Ny. S	P	59 Th	CHF	Irbesartan Bisoprolol Allopurinol Furosemide Lansoprazole Nitrogliserin (nitroglycerin) Nospirinal (aspirin)	Bisoprolol – irbesartan Aspirin – bisoprolol Aspirin – irbesartan Irbesartan – furosemide Bisoprolol – furosemide Aspirin – furosemide	<i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i> Minor	Farmakodinamik sinergis Farmakodinamik antagonis Farmakodinamik antagonis Farmakodinamik antagonis	Furosemide – bisoprolol Furosemide – lansoprazole Aspirin – irbesartan Furosemide – aspirin Aspirin – nitroglycerin	Moderat Moderat Moderat Minor Minor Minor	

									Aspirin – bisoprolol Aspirin – lansoprazole	Minor	
198	Tn. ES	L	92 Th	CHF IHD Hipertensi	Amlodipine Miniaspi (aspirin) Simvastatin Allopurinol Candesartan	Amlodipine – simvastatin Aspirin – candesartan	Serius / mayor <i>Monitor Closely / Moderat</i>	Farmakodinam ik antagonis	Amlodipine – simvastatin Aspirin – amlodipine Aspirin – candesartan	Mayor Moderat Moderat	
199	Ny. M	P	49 Th	CHF Dislipidemi a	ISDN Miniaspi (aspirin) Candesartan Alprazolam Lansoprazole Furosemide	Aspirin – candesartan Candesartan – furosemide Aspirin – furosemide	<i>Monitor Closely / Moderat Monitor Closely</i> Minor	Farmakodinam ik antagonis Farmakodinam ik antagonis	Furosemide – alprazolam Alprazolam – ISDN Furosemide – lansoprazole Alprazolam – candesartan Aspirin – candesartan Furosemide – aspirin	Moderat Moderat Moderat Moderat Moderat Minor Minor	

									Aspirin – lansoprazole		
200	Ny. R	P	59 Th	CHF IHD	Nospirinal (aspirin) Mecobalamin Simvastatin Alprazolam Bisoprolol Candesartan	Bisoprolol – candesartan Aspirin – bisoprolol Aspirin – candesartan	<i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i>	Farmakodinamik sinergis Farmakodinamik antagonis Farmakodinamik antagonis	Alprazolam – bisoprolol Alprazolam – candesartan Aspirin – candesartan Aspirin – bisoprolol	Moderat Moderat Moderat Minor	
201	Tn. S	L	63 Th	CHF Pneumonia PPOK	Mecobalamin Simvastatin Alprazolam Bisoprolol Candesartan Nospirinal (aspirin)	Bisoprolol – candesartan Aspirin – bisoprolol Aspirin – candesartan	<i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i>	Farmakodinamik sinergis Farmakodinamik antagonis Farmakodinamik antagonis	Alprazolam – bisoprolol Alprazolam – candesartan Aspirin – candesartan Aspirin – bisoprolol	Moderat Moderat Moderat Minor	
202	Ny. T	P	67 Th	CHF	Furosemide Spironolactone Digoxin Atorvastatin	Furosemide – digoxin Atorvastatin-digoxin Spironolactone – digoxin	<i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i>	Farmakodinamik sinergis	Furosemide – digoxin Digoxin – atorvastatin	Moderat Moderat Moderat	

					CPG (clopidogrel) Nitrokaf retard (nitroglicerine)	Spironolactone – furosemide			Atorvastatin – clopidogrel Digoxin – spironolactone	Minor	
203	Tn. D	L	83 Th	CHF IHD Hipertensi	CPG (clopidogrel) Simvastatin Bisoprolol Alprazolam Candesartan Amlodipine	Amlodipine – simvastatin Bisoprolol – amlodipine Bisoprolol – candesartan	Serius / mayor <i>Monitor Closely /</i> Moderat	Farmakodinamik sinergis Farmakodinamik sinergis	Amlodipine – simvastatin Alprazolam – amlodipine Alprazolam – bisoprolol Amlodipine – bisoprolol Alprazolam – candesartan	Mayor Moderat Moderat Moderat Moderat	
204	Tn. M	L	65 Th	CHF DM	Simvastatin Metformin Allopurinol Miniaspi (aspirin) Bisoprolol Candesartan	Bisoprolol – candesartan Aspirin – bisoprolol Aspirin – candesartan	<i>Monitor Closely /</i> Moderat <i>Monitor Closely /</i> Moderat	Farmakodinamik sinergis Farmakodinamik antagonis Farmakodinamik antagonis	Aspirin – candesartan Aspirin – bisoprolol	Moderat Minor	

205	Tn. L	L	58 Th	CHF	Omeprazole Bisoprolol Simvastatin Spironolactone Candesartan Nitrokarf retard (nitroglicerine)	Bisoprolol – candesartan Candesartan – spironolactone Bisoprolol – spironolactone	<i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i>	Farmakodinamik sinergis	Spironolactone – candesartan Spironolactone – bisoprolol Omeprazole – simvastatin Nitroglicerine – omeprazole	Mayor Moderat Moderat Minor	
206	Tn. DW	L	61 Th	CHF Nstemi Hipertensi	Fenofibrat Amlodipine Bisoprolol Candesartan CPG (clopidogrel)	Bisoprolol – candesartan Bisoprolol – amlodipine	<i>Monitor Closely / Moderat</i>	Farmakodinamik sinergis Farmakodinamik sinergis	Amlodipine – bisoprolol Clopidogrel – fenofibrate	Moderat Moderat	
207	Tn. SP	L	86 Th	CKD Anemia	Irbesartan Amlodipine Bisoprolol Candesartan Nospirinal (aspirin) Simvastatin	Amlodipine – simvastatin Bisoprolol – amlodipine Bisoprolol – candesartan	Serius / mayor <i>Monitor Closely / Moderat</i>	 Farmakodinamik sinergis Farmakodinamik sinergis	Amlodipine – simvastatin Aspirin – amlodipine Amlodipine – bisoprolol	Mayor Moderat Moderat Moderat	

						Bisoprolol – irbesartan Aspirin – bisoprolol Aspirin – candesartan Aspirin – irbesartan	<i>Monitor Closely / Moderat</i> <i>Monitor Closely Moderat</i> <i>Monitor Closely / Moderat</i>	Farmakodinamik sinergis Farmakodinamik antagonis Farmakodinamik antagonis Farmakodinamik antagonis	Aspirin – irbesartan Aspirin – candesartan Aspirin – bisoprolol	Moderat Minor	
208	Ny. S	P	68 Th	CHF	Lansoprazole Ondancetron Miniaspirin (aspirin) Simvastatin Bisoprolol Furosemide Ranitidine	Aspirin – bisoprolol Bisoprolol – furosemide Aspirin – furosemide	<i>Monitor Closely / Moderat</i> Minor	Farmakodinamik antagonis Farmakodinamik antagonis	Furosemide – bisoprolol Furosemide – lansoprazole Simvastatin – lansoprazole Furosemide – aspirin Aspirin – bisoprolol Aspirin – lansoprazole	Moderat Moderat Moderat Minor Minor Minor	
209	Ny. S	P	73 Th	CHF Hipertensi	Irbesartan Amlodipine Candesartan Bisoprolol	Amlodipine – simvastatin	Serius / mayor		Amlodipine – simvastatin	Mayor Moderat	

					Simvastatin Nospirinal (aspirin)	Bisoprolol – amlodipine Bisoprolol – candesartan Bisoprolol – irbesartan Aspirin – bisoprolol Aspirin – candesartan Aspirin – irbesartan	<i>Monitor</i> <i>Closely</i> / Moderat <i>Monitor</i> <i>Closely</i> / Moderat <i>Monitor</i> <i>Closely</i> / Moderat <i>Monitor</i> <i>Closely</i> / Moderat	Farmakodinam ik sinergis Farmakodinam ik sinergis Farmakodinam ik sinergis Farmakodinam ik antagonis Farmakodinam ik antagonis Farmakodinam ik antagonis	Aspirin – amlodipine Amlodipine – bisoprolol Aspirin – irbesartan Aspirin – candesartan Aspirin – bisoprolol	Moderat Moderat Moderat Minor	
210	Tn. S	L	60 Th	CHF Hipertensi	Diovan (valsartan) Amlodipine CBisoprolol Alprazolam Miniaspi (aspirin) Nitrokaf retard (nitroglicerine)	Bisoprolol – valsartan Aspirin – bisoprolol Bisoprolol – amlodipine Aspirin – valsartan	<i>Monitor</i> <i>Closely</i> / Moderat <i>Monitor</i> <i>Closely</i> / Moderat <i>Monitor</i> <i>Closely</i> / Moderat	Farmakodinam ik sinergis Farmakodinam ik antagonis Farmakodinam ik sinergis Farmakodinam ik antagonis	Alprazolam – nitroglicerine Alprazolam – amlodipine Apirin – amlodipine Nitroglicerine – amlodipine Alprazolam – bisoprolol Amlodipine – bisoprolol	Moderat Moderat Moderat Moderat Moderat Moderat Moderat	

									Alprazolam – valsartan Aspirin – valsartan Bisoprolol – valsartan Aspirin – nitroglicerine Aspirin – bisoprolol	Moderat Minor Minor	
211	Ny. S	P	66 Th	CHF Hipokalemi a Bradikardi	Kompolac Furosemide Beraprost Miniaspi (aspirin) Candesartan Bisoprolol	Bisoprolol – candesartan Aspirin – bisoprolol Aspirin – candesartan Candesartan – furosemide Bisoprolol – furosemide Aspirin – furosemide	<i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i>	Farmakodinamik sinergis Farmakodinamik antagonis Farmakodinamik antagonis	Furosemide – bisoprolol Aspirin – candesartan Furosemide – aspirin Aspirin – bisoprolol	Moderat Moderat Minor Minor	
212	Ny. T	P	61 Th	CHF	Lansoprazole Ondancetron	Aspirin – bisoprolol	<i>Monitor Closely / Moderat</i>	Farmakodinamik antagonis	Furosemide – bisoprolol	Moderat Moderat	

					Miniaspi (aspirin) Simvastatin Bisoprolol Furosemide Ranitidine	Bisoprolol – furosemide Aspirin – furosemide	Minor	Farmakodinam ik antagonis	Furosemide – lansoprazole Simvastatin – lansoprazole Furosemide – aspirin Aspirin – bisoprolol Aspirin – lansoprazole	Moderat Minor Minor Minor	
213	Tn. PS	L	62 Th	CHF	Nospirinal (aspirin) Simvastatin Bisoprolol Lansoprazol e	Aspirin – bisoprolol	<i>Monitor Closely / Moderat</i>	Farmakodinam ik antagonis	Simvastatin – lansoprazole Aspirin – bisoprolol Aspirin – lansoprazole	Moderat Minor Minor	
214	Ny. S	P	64 Th	CHF IHD	Lansoprazol e Nospirinal (aspirin) Bisoprolol Simvastatin	Aspirin – bisoprolol	<i>Monitor Closely / Moderat</i>	Farmakodinam ik antagonis	Simvastatin – lansoprazole Aspirin – bisoprolol Aspirin – lansoprazole	Moderat Minor Minor	

					Nitrokaf retard (nitroglicerine)						
215	Ny. P	P	90 Th	CHF IHD	Alprazolam Nospirinal (aspirin) Lansoprazole Simvastatin Bisoprolol Candesartan	Bisoprolol – candesartan Aspirin – bisoprolol Aspirin – candesartan	<i>Monitor Closely / Moderat Monitor Closely / Moderat</i>	Farmakodinam ik sinergis Farmakodinam ik antagonis Farmakodinam ik antagonis	Alprazolam – bisoprolol Simvastatin – lansoprazole Alprazolam – candesartan Aspirin – candesartan Aspirin – bisoprolol Aspirin – lansoprazole	Moderat Moderat Moderat Moderat Minor Minor	
216	Tn. P	L	57 Th	CAD CHF	Miniaspi (aspirin) Alprazolam CPG (clopidogrel) Lansoprazole Atorvastatin	Aspirin – bisoprolol Aspirin – clopidogrel Lansoprazole – clopidogrel	<i>Monitor closely/ Moderat Monitor Closely / Moderat</i>	Farmakodinam ik antagonis Farmakodinam ik sinergis	Alprazolam – nitroglicerine Alprazolam – bisoprolol Lansoprazole – atorvastatin	Moderat Moderat Moderat Moderat Moderat	

					Nitrokaf retard (nitroglicerine) Bisoprolol				Aspirin – clopidogrel Lansoprazole – clopidogrel Atorvastatin – clopidogrel Aspirin – nitroglicerine Aspirin – bisoprolol Aspirin – lansoprazole	Moderat Minor Minor Minor	
217	Tn. RH	L	46 Th	CHF IHD DM	Furosemide Miniaspi (aspirin) Simvastatin Bisoprolol Candesartan Irbesartan Allopurinol Metformin	Bisoprolol – candesartan Bisoprolol – irbesartan Aspirin – bisoprolol Aspirin – candesartan Aspirin – irbesartan Candesartan – furosemide	<i>Monitor</i> <i>Closely</i> / Moderat <i>Monitor</i> <i>Closely</i> / Moderat <i>Monitor</i> <i>Closely</i> / Moderat <i>Monitor</i> <i>Closely</i> / Moderat	Farmakodinam ik sinergis Farmakodinam ik sinergis Farmakodinam ik antagonis Farmakodinam ik antagonis Farmakodinam ik antagonis	Furosemide – bisoprolol Furosemide – metformin Aspirin – irbesartan Aspirin – candesartan Furosemide – aspirin Aspirin – bisoprolol	Moderat Moderat Moderat Moderat Minor Minor	

						Irbesartan – furosemide Bisoprolol – furosemide	<i>Monitor Closely</i> Moderat				
						Aspirin – furosemide Metformin – furosemide	Minor Minor	Farmakodinamik antagonis			
218	Ny.S	P	55 Th	CHF IHD	Ciprofloxacin Bisoprolol Candesartan Lansoprazole Miniaspi (aspirin)	Bisoprolol – candesartan Aspirin – bisoprolol Aspirin – candesartan Aspirin – ciprofloxacin	<i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i>	Farmakodinamik sinergis Farmakodinamik antagonis Farmakodinamik antagonis	Ciprofloxacin – aspirin Aspirin – candesartan Aspirin – bisoprolol Aspirin – lansoprazole	Moderat Moderat Minor Minor	
219	Tn. GS	L	65 Th	CHF DM	Bisoprolol Nospirinal (aspirin) Metformin Candesartan Beraprost	Bisoprolol – candesartan Aspirin – bisoprolol Aspirin – candesartan	<i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i>	Farmakodinamik sinergis Farmakodinamik antagonis Farmakodinamik antagonis	Aspirin – candesartan Aspirin – bisoprolol	Moderat Minor	
220	Tn. S	L	58 Th	CHF DM	CPG (clopidogrel) Bisoprolol	Tidak ada interaksi			Atorvastatin – clopidogrel	Moderat	

					Atorvastatin Nitrogliserin retard (nitroglycerin) ISDN Metformin						
221	Ny. SM	P	62 Th	CHF CAD Stable angina DM	Metformin Glimepiride Furosemide Spironolactone HCT CPG (clopidogrel) Concor (bisoprolol) ISDN	Spironolactone – furosemide Spironolactone – hydrochlorothiazide Bisoprolol – spironolactone Bisoprolol – furosemide Bisoprolol – hydrochlorothiazide Furosemide – hydrochlorothiazide Furosemide –	Monitor Closely / Moderat Monitor Closely / Moderat Monitor Closely / Moderat Monitor Closely / Moderat Monitor Closely / Moderat Monitor Closely / Moderat Minor		Furosemide – hydrochlorothiazide Furosemide – bisoprolol Hydrochlorothiazide – bisoprolol Spironolactone – bisoprolol Furosemide – metformin Hydrochlorothiazide – metformin Spironolactone – metformin	Moderat Moderat Moderat Moderat Moderat Moderat Moderat Moderat	

						hydrochlorot hiazide	Minor	Farmakodinam ik antagonis	Furosemide – glimepiride	Moderat	
						Metformin – furosemide	Minor	Farmakodinam ik antagonis	Hydrochloro thiazide – glimepiride	Moderat	
						Hydrochloro thiazide – glimepiride			Bisoprolol – glimepiride	Moderat	
						Hydrochloro thiazide – metformin			Metformin – glimepiride	Minor	
									Glimepiride – clopidogrel		
222	Tn. D	L	60 Th	CAD	Candesartan Amlodipine Clonidine Bisoprolol Spironolacto ne Furosemide CPG	Clonidine – bisoprolol	Serius / mayor	Farmakodinam ik sinergis	Clonidine – bisoprolol	Mayor	
						Bisoprolol – amlodipine	<i>Monitor</i>	Farmakodinam ik sinergis	Spironolacto ne – candesartan	Mayor	
						Bisoprolol – candesartan	<i>Closely /</i> Moderat	Farmakodinam ik sinergis		Moderat	
						Bisoprolol – spironolacto ne	<i>Monitor</i> <i>Closely /</i> Moderat		Furosemide – bisoprolol	Moderat	
						Bisoprolol – furosemide	<i>Monitor</i> <i>Closely /</i> Moderat		Spironolacto ne – bisoprolol	Moderat	
						Candesartan – furosemide			Amlodipine – bisoprolol		

						Spironolactone – furosemide	<i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i>				
223	Tn. BP	L	72 Th	CHF IHD	Gemfibrozil Bisoprolol Miniaspi (aspirin) Candesartan Lansoprazole Furosemide Spironolactone	Bisoprolol – candesartan Aspirin – bisoprolol Aspirin – candesartan Aspirin – spironolactone Spironolactone – furosemide Bisoprolol – spironolactone Bisoprolol – furosemide Candesartan – furosemide	<i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i> <i>Minor</i>	Farmakodinamik sinergis Farmakodinamik antagonis Farmakodinamik antagonis Mekanisme interaksi tidak spesifik Farmakodinamik antagonis	Spironolactone – candesartan Furosemide – bisoprolol Spironolactone – bisoprolol Furosemide – lansoprazole Aspirin – candesartan Furosemide – aspirin Aspirin – spironolactone Aspirin – bisoprolol	Mayor Moderat Moderat Moderat Moderat Minor Minor Minor Minor	

						Aspirin – furosemide			Aspirin – lansoprazole		
224	Ny. S	P	65 Th	CHF CAD DM	Aspilet (aspirin) Candesartan Bisoprolol Nitrokaf retard (nitroglicerine) Novorapid (insulin aspart) Atorvastatin	Bisoprolol – candesartan Aspirin – bisoprolol Aspirin – candesartan Aspirin – insulin aspart Candesartan – insulin aspart	<i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i> <i>Monitor Closely</i>	Farmakodinamik sinergis Farmakodinamik antagonis Farmakodinamik antagonis Farmakodinamik sinergis Mekanisme interaksi tidak spesifik	Aspirin – candesartan Aspirin – insulin aspart Bisoprolol – insulin aspart Candesartan – insulin aspart Aspirin – nitroglicerine Aspirin – bisoprolol	Moderat Moderat Moderat Moderat Minor Minor	
225	Tn. AS	L	60 Th	CHF CAD DM	CPG (clopidogrel) Furosemide Simvastatin Metformin Candesartan Mecobalamine	Candesartan – furosemide Metformin – furosemide Furosemide – metformin Metformin – mecobalamine	<i>Monitor Closely / Moderat</i> Minor Minor Minor	Mekanisme interaksi tidak spesifik Mekanisme interaksi tidak spesifik	Furosemide – metformin	Moderat	

226	Ny. D	P	65 Th	Hipokalemi a CHF	Concor (bisoprolol) Simvastatin Atorvastatin Spironolactone Furosemide Candesartan	Bisoprolol – candesartan Simvastatin – atorvastatin Spironolactone – furosemide Bisoprolol – spironolactone Candesartan – spironolactone Candesartan – furosemide Bisoprolol – furosemide	<i>Monitor Closely / Moderat Monitor Closely / Moderat Monitor Closely / Moderat Monitor Closely / Moderat Monitor Closely / Moderat</i>	Farmakodinamik sinergis	Spironolactone – candesartan Furosemide – bisoprolol Spironolactone – bisoprolol Simvastatin – atorvastatin	Mayor Moderat Moderat Moderat	
227	Ny. K	P	64 Th	CAD CHF	Bisoprolol Diovan (valsartan) CPG (clopidogrel) Atorvastatin ISDN Candesartan	Bisoprolol – candesartan Bisoprolol – valsartan Atorvastatin – valsartan	<i>Monitor Closely / Moderat Monitor Closely / Moderat</i>	Farmakodinamik sinergis Farmakodinamik sinergis	Bisoprolol – valsartan Atorvastatin – clopidogrel	Moderat Moderat	

228	Tn. LW	L	76 Th	IHD CHF DM	Metformin Simvastatin Diovan Furosemide Amlodipine Candesartan	Amlodipine – simvastatin Amlodipine – metformin Simvastatin – valsartan Candesartan – furosemide Valsartan – furosemide Furosemide – metformin	Serius / mayor <i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i> Minor	Farmakodinamik antagonis	Amlodipine – simvastatin Furosemide – metformin	Mayor Moderat	
229	Ny. P	P	61 Th	CHF DM IHD	Lansoprazole Bisoprolol Nitrogliserin retard (nitrogliserin) Allopurinol Candesartan Simvastatin Alprazolam Furosemide	Bisoprolol – candesartan Lansoprazole – clopidogrel Candesartan – furosemide Bisoprolol – furosemide Furosemide – metformin	<i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i> <i>Monitor Closely / Moderat</i> <i>Monitor Closely</i> Minor	Farmakodinamik sinergis Mekanisme interaksi tidak spesifik	Furosemide – alprazolam Alprazolam – nitrogliserin Furosemide – bisoprolol Alprazolam – bisoprolol Furosemide – metformin	Moderat Moderat Moderat Moderat Moderat Moderat	

					CPG (clopidogrel) Metformin				Furosemide – lansoprazole Simvastatin – lansoprazole Lansoprazol e – clopidogrel Alprazolam – candesartan	Moderat Moderat	
230	Tn. AL	L	65 Th	CHF DM IHD	Lansoprazol e Bisoprolol Nitrokaf retard (nitroglicerine) Allopurinol Candesartan Simvastatin Alprazolam Furosemide CPG (clopidogrel) Metformin	Bisoprolol – candesartan Lansoprazol e – clopidogrel Candesartan – furosemide Bisoprolol – furosemide Furosemide – metformin	<i>Monitor Closely / Moderat Monitor Closely / Moderat Monitor Closely</i> Minor	Farmakodinamik sinergis Mekanisme interaksi tidak spesifik	Furosemide – alprazolam Alprazolam – nitroglicerine Furosemide – bisoprolol Alprazolam – bisoprolol Furosemide – metformin Furosemide – lansoprazole	Moderat Moderat Moderat Moderat Moderat Moderat Moderat	

									Simvastatin – lansoprazole Lansoprazol e – clopidogrel Alprazolam – candesartan	Moderat	
--	--	--	--	--	--	--	--	--	---	---------	--

